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CHAPTER 4 
MODULATION OF IMMUNE-RELATED CELL SURFACE MOLECULES BY 
CYTOKINES AND a-MSH. 
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4.1 INTRODUCTION. 
Several hypotheses exist to explain the etiology of vitiligo (as discussed in Section 1.4). 
However, it is unclear whether the melanocytes (and perhaps other cells of the 
epidermis e. g. keratinocytes) of vitiligo patients have some intrinsic defect or whether 
the disease results from an autoimmune response. There is strong evidence for an 
autoimmune involvement (discussed fully in Section 1.4.3); for example, patient sera 
have been found to contain various antibodies relating to melanocytes and melanogenic 
enzymes (e. g. Naughton et al, 1983a & b; Bystryn & Naughton, 1985; Cui et al, 1992; 
Yu et al, 1993; Merimsky et al, 1994; Song et al, 1994b; Cui et al, 1995; Hann & Kim, 
1995; Baharav et al, 1996; Kemp et al, 1997a & b; see Section 1.4.3b for further 
examples) which have been shown to induce immune damage to cultured human 
melanocytes (Norris et al, 1988; Park et al, 1991; Cui et al, 1993; Yu et al, 1993; 
Abdel-Naser et al, 1994). In some studies the level and activity of these antibodies have 
been found to correlate with disease status (Naughton et al, 1986; Harning et al, 1991). 
Abnormal, i. e. increased, expression of ICAM-1 and MHC class II have been shown for 
melanocytes in perilesional biopsies of vitiligo (Al Badri et al, 1993a) and in ocular 
melanocytes of patients with VKH (a disease in which some patients develop vitiligo- 
like patches) (Sakamoto et al, 1991). Infiltration of T cells and macrophages parallels 
the loss of pigment and the disappearance of melanocytes in inflammatory vitiligo (Le 
Poole et al, 1996b) although it is uncertain whether the presence of these T cells relates 
to a primary defect of the immune system. Melanocytes have been shown to present 
molecules and function as accessory cells of the skin immune system (Le Poole et al, 
1993b). 
An interesting theory has arisen in recent years suggesting that pro-opiomelanocortin 
(POMC) peptides may play a role in aetiology of vitiligo (Liu et al, 1995). Liu et al. 
(1995) detected high levels of IR a-, ß- and y-MSH in the epidermis in vitiligo lesions 
and proposed that overproduction of the peptides or a defective receptor may cause the 
disease. Recent perspectives on a-MSH, which has wide biological activities (reviewed 
by Eberle, 1988) have led to it being viewed as a neuroimmunomodulatory peptide that 
inhibits fever and all major forms of experimental inflammation through central nervous 
system and peripheral melanocortin receptors. Current concepts of the anti- 
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inflammatory actions of a-MSH suggest that it acts through the MC1R on macrophages 
and neutrophils to inhibit macrophage activation and neutrophil migration (as reviewed 
in Lipton & Catania, 1997). 
Skin is now considered to be one of several non-pituitary tissues in which POMC- 
derived peptides such a-MSH and ACTH and the parent molecule are produced (Thody 
et al, 1983; Farooqui et al, 1993; Schauer et al, 1994; Iyengar, 1995; Kippenberger et 
al, 1995; Slominski et al, 1995; Chakraborty et al, 1996; Wintzen et al, 1996; Teofoli 
et al, 1997; Wakamatsu et al, 1997; Can et al, 1998). Both melanocytes and 
keratinocytes play a role in peptide production and UV exposure increases this 
production. Melanoma cells have also been shown to have IR MSH (Lunec et al, 1990; 
Loir et al, 1991; Nagahama et al, 1998) and express ACTH (Iyengar, 1995; Nagahama 
et al, 1998). Additional POMC-derived peptides, ß-lipotropic hormone and ß- 
endorphin, are produced in keratinocytes (Wintzen et al, 1996). The main regulator of 
POMC expression in the stress response pituitary-hypothalamis-axis, corticotropin 
releasing factor, has also been shown to be produced by melanocytes (Slominski et al, 
1995 & 1996). The availability of these peptides would be consistent with the 
melanocyte occupying a stress/defence role in the skin and a-MSH/ACTH playing a 
major role in the regulation of the melanocyte beyond pigment production. Local 
inflammation is a feature of excess UV exposure in human skin. Patients with vitiligo 
may experience inflammation during the development of their condition but this is 
rarely observed clinically (Grab & Wise, 1948; Buckley & Lobitz, 1953; Michaelsson, 
1968; Ishii & Hamada, 1981; Le Poole et al, 1996; Horn & Abanmi, 1997; Yagi et al, 
1997). Under such circumstances one would expect upregulation of adhesion molecules 
on keratinocytes and melanocytes and interactions of immune cells with these cells as 
described in inflammatory vitiligo (Le Poole et al, 1996; Horn & Abanmi, 1997; Yagi et 
al, 1997). ICAM-1 expression is an obligatory requirement (but not the sole pre- 
requisite) for T cell binding to cells and is stimulated on melanocytes in culture 
following exposure to a variety of cytokines (Yohn et al, 1990; Krasagakis et al, 1991; 
Kinnbauer et al, 1992; Le Poole et al, 1993b; Krasagakis et al, 1995). Following UV 
exposure, human melanocytes respond with an increase in pigment synthesis (as 
discussed in Section 3.5.3). Several studies have suggested that melanin precursors, 
particularly dopa and DHI are inherently cytotoxic to the melanocyte (e. g. Wick et al, 
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1977; Fujita et al, 1980; Pawelek et al, 1980; Urabe et al, 1994). This, combined with 
an increase in adhesion molecules expression by UV/cytokines on melanocytes, might 
act to make these cells a target for infiltrating T cells. 
The purpose of this study was to investigate whether melanocytes in patients with 
vitiligo are intrinsically more susceptible to immune attack. If the melanocytes have an 
inherent defect such as the described abnormalities in the RER (Boissy et al, 1991; Im 
et al, 1994), an increase of adhesion molecule expression might result, which would 
promote enhanced interaction with immune cells or that vitiligo melanocytes would be 
particularly susceptible to cytokines such as IFN-y and TNF-a. This possibility was 
examined by comparing basal and cytokine-stimulated expression of the MHC class I 
and class II molecules and ICAM-1 on normal and vitiligo melanocytes. Additionally, 
one biological activity of a-MSH in skin might be to assist melanocytes to survive the 
process of pigmentation, especially during UV associated inflammation by acting as an 
immunomodulatory molecule. A recent paper by Luger (1998) has also proposed a 
major role for the POMC peptides in modulating UV reponses in skin. a-MSH 
opposition of cytokine-stimulated adhesion molecule expression on melanocytes might 
prevent premature interaction between cells of the immune system and melanocytes 
undergoing active pigment synthesis. 
4.2 MODULATION OF ICAM-1 EXPRESSION IN NORMAL AND VITILIGO 
MELANOCYTES. 
ICAM-1 is one of several cofactors involved in the binding and activation of T cells. It 
is also one of the most studied cell surface molecules in preliminary examinations of 
whether a cell may be able to interact with cells of the immune system. In this section 
several different stimuli, e. g. cytokines and media, which may play a role in the 
regulation of ICAM-1 have been examined and the most effective media were used to 
compare whether there are differences between normal and vitiligo melanocytes. 
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4.2.1 ICAM-1 expression on normal melanocytes in response to increasing 
concentrations of IFN-y and TNF-a. 
Initial studies were carried out to determine a suitable concentration at which to use the 
cytokines for further comparative work. A dose response relationship to IFN-y or TNF- 
a on ICAM-1 expression (Figures 4.1a-d) was assessed in melanocytes from four 
different donors. Melanocytes were cultured for 5 days under experimental conditions 
in 12 well plates, with cytokines added for the final 24 hours. ICAM-1 was analysed 
using a cell-based ELISA method (as described in Section 2.9). ICAM-1 data were 
corrected for isotype antibody, wells that contained no cells and for 104 cells. 
ICAM-1 expression on melanocytes cultured on plastic or fibroblast-derived ECM was 
increased in a dose dependent manner in response to the cytokines. O. 1U/ml IFN-y was 
the minimal concentration required to see an increase in ICAM-1 expression on 
melanocytes cultured on plastic in all three media (Figure 4.1a), maximal effects were 
achieved at 500U/ml IFN-y in medium 1, and at 100U/ml IFN-y in media 10 and 24. 
Melanocytes cultured on ECM achieved maximal expression of ICAM-1 in response to 
IFN-y by 100U/ml (Figure 4.1b). 100U/ml TNF-a, was the minimal concentration 
required for increased ICAM-1 expression in the melanocyte culture set up on plastic, 
with the maximal response seen at 500U/ml (Figure 4.1c). The melanocytes cultured 
on ECM had a broader spectrum with increases in ICAM-1 expression from 1U/ml and 
a maximal response achieved between 100 and 500U/ml TNF-a, depending on the 
media composition (Figure 4.1d). From this work it was decided that a concentration 
of 100U/ml be used for the comparative studies of cytokines on melanocytes. 
4.2.2. Comparison of ICAM-1 expression stimulated by IFN-y and TNF-a in 
normal melanocytes cultured on plastic or fibroblast-derived ECM. 
The effects of 100U/ml IFN-y or TNF-a on ICAM-1 expression were investigated in 
melanocytes from several different donors cultured on plastic or fibroblast derived ECM 
(Tables 4.1a and 4.1b illustrate the results for the individual experiments). The 
protocol was the same as in Section 4.2.1, although some of the experiments in this 
section were conducted in 24 well plates (in duplicate or triplicate) instead of 12 wells. 
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Figure 4.1 Expression of ICA I-1 in normal melanocytes in response to 
increasing concentrations of IFN-y or TNF-a. Passage 4 melanocytes, with a 
different donor for each experiment, were seeded at 0.3 to 1x 105 cells/well (12 well 
plate) on plastic (a and c) or fibroblast-derived ECM (as described in Section 2.5.3) 
(b and d) in maintenance media A or B and allowed to adhere for 24 hours (one well 
for ICAM-1 staining and one well for isotype antibody staining). Cells were then 
cultured for 5 days in either media 1 (closed circle), 10 (closed square) or 24 (closed 
triangle) (refer to Table 2.2 for media composition). IFN-y (1 to 500U/ml) (a and b) 
or TNF-a (1 to 50OU/ml) (c and d) were added for the final 24 hours. ICAM-1 
expression was determined by a cell-based ELISA method (as described in Section 
2.9). The results illustrate ICAM-1 expression as O. D. 492-620nm/104 cells x 10-3 
for each condition. (Cell number was calculated by cell counts on 1 parallel well for 
each condition, results not shown). 
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In all three experimental media (1,10 or 24), there was a low mean constitutive ICAM- 
1 expression irrespective of plating surface (Figure 4.2). There were no significant 
differences between the basal ICAM-1 expression of cells cultured on plastic and ECM. 
Media composition did not influence constitutive ICAM-1 expression of normal 
melanocytes irrespective of plating surface. 
Both IFN-y and TNF-a significantly increased ICAM-1 expression in all three media for 
cells cultured on plastic (Table 4.1a and Figures 4.2a-c). N-fold increases in ICAM-1 
expression ranged from 5 fold (p<0.01, IFN-y supplemented medium 24) to 26 fold 
(p<0.001, IFN-y supplemented medium 1). Although ICAM-1 expression was 
increased by IFN-y and TNF-a under all media for melanocytes cultured on ECM, 
statistical significance was not achieved for all parameters due to donor to donor 
variability (Table 4.1b and Figures 4.2d-f). Significant n-fold increases for cells 
cultured on ECM ranged from 7 fold (p<0.05, IFN-y supplemented medium 24) to 46 
fold (p<0.05, TNF-(x supplemented medium 1) on ECM. Fibroblast-derived ECM 
increased the expression of ICAM-1 by 2 fold (p<0.05) in response to TNF-a when 
cells were cultured on ECM in comparison to cells cultured on plastic. However, under 
all other conditions examined there was no significant differences in ICAM-1 
expression of melanocytes cultured on plastic and ECM. 
Media played a significant role in determining the level of ICAM-1 expression achieved 
in response to the cytokines. Melanocytes cultured in medium 24 always had the lowest 
level of ICAM-1 expression. For melanocytes cultured on plastic, ICAM-1 expression 
in response to IFN-y was 5 fold and 4.6 fold lower in medium 24 than that seen in media 
1 (p<0.001) and media 10 (p<0.001) respectively, while in response to TNF-a, ICAM-1 
expression was 2 fold and 3.6 fold lower in medium 24 than in media 1 (p<0.01) and 
media 10 (p<0.01) respectively. For melanocytes cultured on ECM, ICAM-1 
expression in response to IFN-y was 6 fold and 4 fold lower in medium 24 than that 
seen in media 1 (p<0.0) and media 10 (p<0.0) respectively. The ICAM-1 expression in 
response to TNF-a was not significantly different between cells cultured in media 1,10 
or 24, when the cells were plated on ECM. IFN-y stimulated a 2.8 fold and 1.3 fold 
Figure 4.2 Effect of IFN-y and TNF-a on ICAM-1 expression in normal 
melanocytes cultured on plastic or fibroblast-derived ECM. Melanocytes were 
cultured on plastic (a-c) or fibroblast-derived ECM (prepared as described in Section 
2.5.3) (d-f) for 5 days under experimental media 1 (a, d), 10 (b, e) or 24 (c, f) (as 
described in Table 4.1 for the individual experiments). Cells were untreated (closed 
bar) or treated with 100U/ml IFN-y (open bar) or 100U/ml TNF-a (hatched bar) for the 
final 24 hours before ICAM-1 was analysed (as described in Section 2.9). The results 
show the mean ICAM-1 expression (O. D. 492-620nm/104 cells x 10,3) ± SEM of 9 
experiments using melanocytes from different donors for cells cultured on plastic and of 
3 to 4 experiments using melanocytes from different donors for cells cultured on ECM. 
Cytokine-stimulated ICAM-1 expression differing from basal expression is indicated by 
*=p<0.05, **=p<0.01 or ***=p<0.001 based on Student's paired t-test, by e=p<0.05 
based on Student's unpaired t-test, or by W=p<0.05 based on the Mann Whitney test. 
Significant differences between IFN-y- and TNF-a-stimulated ICAM-1 expression are 
indicated by H *=p<0.05 or H **=p<0.01 based on Student's paired t-test. 
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higher expression of ICAM-1 than TNF-a in cells cultured on plastic in media 1 
(p<0.001) and 10 (p<0.05) respectively. In cells cultured on ECM, the expression of 
ICAM-1 in response to IFN-y and TNF-a was similar. 
Therefore, ICAM-1 expression was stimulated by the incubation of melanocytes with 
100U/ml IFN-y or TNF-a (24 hours) irrespective of plating substrata. Media played a 
role in regulating the level of ICAM-1 expression obtained in response to the cytokines 
with lowest levels seen in medium 24. IFN-y was the most potent stimulator of ICAM- 
1 expression in melanocytes cultured on plastic but no significant differences were seen 
between the two cytokines when cells were cultured on ECM. 
4.2.3. Comparison of TNF-a-stimulated ICAM-1 expression in 17 different media 
variants. 
To analyse the effect of media further, melanocytes from three different donors (2 at P4 
and one at P1) were cultured under 17 different experimental media for 5 days, and 
100U/ml TNF-a was added for the final 24 hours. 
Constitutive expression of ICAM-1 was not affected by the different media variants 
(Figure 4.3). TNF-a stimulated ICAM-1 expression in all media although there was a 
lot of donor to donor variability (as shown in Table 4.2). Significant increases in 
ICAM-1 were only seen in media 3 (containing FCS/BPE/PMA, 9 fold), 4 (containing 
FCS/BPE/CT, 26 fold), 8 (containing BPE/PMA/CT, 8 fold), 10 (containing FCS/BPE, 
5 fold) and 21 (containing BPE, 54 fold) (all p<0.05) (Figure 4.3). BPE was a common 
factor in all the media where a significant response was seen. The basal levels in these 5 
media were low. Unlike in Section 4.2.2, a significant increase in ICAM-1 expression 
in response to TNF-a in medium 1 was not seen due to the donor to donor variability. 
While media components were unable to influence constitutive ICAM-1 expression, 
they did play a role in influencing the level of ICAM-1 expression reached in response 
to TNF-a. 
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4.2.4. Effect of UVR on melanocyte basal and cytokine-stimulated expression of 
ICAM-1. 
UV irradiation is known to have direct and indirect influences on melanocyte behaviour 
as discussed in Chapter 3. Therefore the influence of UVB on ICAM-1 expression was 
examined in melanocytes from three different donors (cell number analysed in parallel 
wells as described in Section 3.3.2). IFN-y was examined in one of the media variants 
(medium 10) as a positive control. 
Basal ICAM-1 expression was low in all media (Figure 4.4). Overall UVB did not 
significantly alter ICAM-1 expression except at timepoint 2 where there was a 
significant decrease in ICAM-1 expression by 88% in medium 24 (p<0.05) (Figure 
4.4b). 
At all three timepoints, IFN-y, significantly stimulated ICAM-1 expression in medium 
10, by 237 fold (timepoint 1, p<0.05) (Figure 4.4a), by 26 fold (timepoint 2, p<0.01) 
(Figure 4.4b) and by 17 fold (timepoint 3, p<0.05) (Figure 4.4c). (It should be noted 
that the mean basal levels in medium 10 changed from 0.1 at timepoint 1 to 3.8 by 
timepoint 3 and the IFN-y levels changed from 23.7 at timepoint 1 to 64.2 at timepoint 
3). UVB increased IFN-y-stimulated ICAM-1 expression in two of the three 
experiments at timepoint 1 (Table 4.3a). At timepoint 2, there was a significant 45% 
increase in IFN-y-stimulated ICAM-1 expression in response to UVB (p<O. 05) (Table 
4.3b and Figure 4.4b), while at timepoint 3, in the 2 completed experiments there were 
only slight increases (Table 4.3c). 
In conclusion, UVB alone did not upregulate ICAM-1 expression under any media 
conditions examined. UVB did slightly enhance the response to IFN-y in one of these 
media examined. 
Figure 4.4 Effect of UVB and IFN-y on normal melanocyte ICA11I-1 expression. 
Melanocytes were sham irradiated (closed bar) or irradiated (open bar) daily for 1 (a), 4 
(b) or 7 (c) days with 143mJ/cm2 of UVB (as described in Table 4.3 for individual 
experiments and Section 2.6). 100U/ml IFN-y was added for 24 hours to the 
appropriate cells in medium 10 after the final irradiation for each protocol and then 
ICAM-1 was analysed (as described in Section 2.9) for each time point. The data 
shows the mean ICAM-1 expression (O. D. 492-620nm/104 cells x 10"3) ± SEM of 3 
experiments using melanocytes from different donors. Significant differences in 
ICAM-1 expression in response to UVB are indicated by *=p<0.05 based on Student's 
paired t-test, while significant differences in ICAM-1 expression in response to IFN-y 
are indicated by H *=p<0.05 or H **=p<0.01 based on Student's paired t-test. Only 
two experiments were complete where cells were irradiated on 7 occasions therefore the 
results of these are not shown (absence of open bars in c). 
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4.2.5 Comparison of ICAM-1 expression in normal and vitiligo melanocytes 
cultured on plastic. 
Media and cytokines had prominent effects on ICAM-1 expression in normal 
melanocytes. Therefore the ICAM-1 response to cytokines was analysed in normal and 
vitiligo melanocytes under three media varying in mitogenic potential. A mean 
constitutive expression of ICAM-1 was seen under all three media conditions, in both 
normal and vitiligo melanocytes (Figure 4.5), but not all cultures exhibited basal 
ICAM-1 expression (Table 4.1a and 4.1c). There were no significant differences in 
basal levels between normal and vitiligo melanocytes, and media did not influence basal 
ICAM-1 expression. 
IFN-y and TNF-a significantly increased ICAM-1 levels in both normal and vitiligo 
melanocytes when cultured in media 1 (Figures 4.5a and 4.5d respectively) and 10 
(Figures 4.5b and 4.5e respectively). In normal melanocytes, the n-fold values ranged 
from 8 fold (p<0.05, TNF-a supplemented medium 10) to 75 fold (p<0.01, IFN-y 
supplemented medium 1), while in vitiligo melanocytes the n-fold values ranged from 6 
fold (p<0.01, TNF-a supplemented medium 1) to 17 fold (p<0.05, IFN-y supplemented 
media 1 and 10). Normal melanocyte ICAM-1 expression was significantly increased 
(10 fold) by IFN-y (p<0.05) in medium 24 (Figure 4.5c) while ICAM-1 expression was 
significantly increased (10 fold) by TNF-a (p<0.05) in vitiligo melanocytes (Figure 
4.5f). ICAM-1 expression was much lower in medium 24 than in media 1 and 10 in 
response to the cytokines as in accordance with the results in Section 4.4.2. IFN-y had a 
significant 2.7 fold stronger effect on ICAM-1 expression than TNF-a, in medium 1 
(p<0.01) and a significant 1.7 fold stronger effect in medium 10 (p<0.05) in normal 
melanocytes. In vitiligo melanocytes, IFN-y was stronger than TNF-a by 3 fold in 
medium 1 (p<0.05). 
The expression of ICAM-1 in response to cytokines was not significantly different 
between normal and vitiligo melanocytes under any of the conditions examined. Both 
IFN-y and TNF-a increased ICAM-1 expression in all 3 media and IFN-y was generally 
the most potent stimulator of ICAM-1 expression in normal and vitiligo melanocytes. 
Figure 4.5 Effect of IFN-y and TNF-a on normal and vitiligo melanocyte ICAM-1 
expression. Normal (a-c) and vitiligo (d-f) melanocytes were cultured for 5 days under 
experimental media 1 (a and d), 10 (b and e) or 24 (c and f) (as described in Table 4.1 
for the individual experiments). Cells were untreated (closed bar) or treated with 
100U/ml IFN-y (open bar) or 100U/ml TNF-a (hatched bar) during the final 24 hours 
before ICAM-1 was analysed (as described in Section 2.9). The results show the mean 
ICAM-1 expression (O. D. 492-620nm/104 cells x 10-3) ± SEM of 4 experiments using 
melanocytes from 4 different normal subjects and 4 different vitiligo patients. 
Cytokine-stimulated ICAM-1 expression differing from basal expression is indicated by 
*=p<0.05 and **=p<0.01 based on Student's paired t-test. Significant differences 
between IFN-y and TNF-a-stimulated ICAM-1 expression are indicated by H *=p<0.05 
and H **=p<0.01, based on Student's paired t-test. 
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4.3 MODULATION OF CYTOKINE-STIMULATED ICAM-1 EXPRESSION IN 
NORMAL MELANOCYTES BY a-MSH AND RELATED PRO- 
OPIOMELANOCORTIN PEPTIDES. 
Melanocytes have the capacity to express immune related cell surface molecules (as 
discussed in Section 4.2, and Sections 4.4-4.5). a-MSH is known to be produced in 
response to UV by cells in the epidermis. In response to UV, inflammation can occur, 
and the melanocyte could become a target for the cells of the immune system. In 
addition to a pigmentary role (discussed in Chapter 3), a-MSH has other biological 
actions, such as anti-inflammatory actions. In this section, preliminary work to examine 
a role for a-MSH in damping down the effect of cytokines on the expression of ICAM-1 
commenced. 
4.3.1 Effect of culture media on the ability of TNF-a to stimulate ICAM-1 
expression and immunomodulatory effects of a-MSH. 
Melanocytes from 3 different donors were initially used to examine the possiblility that 
a-MSH may be able to oppose cytokine-stimulated ICAM-1 expression. The three 
commonly used experimental medium 1,10 and 24 were employed in this preliminary 
study. Although there was considerable donor to donor variation in the response to 
TNF-a (as illustrated in Table 4.4), TNF-a-stimulated ICAM-1 expression on 
melanocytes in media 1 and 10 (7 fold increase of ICAM-1 expression in medium 10, 
failing to achieve statistical significance). In medium 24, there was a2 fold increase in 
ICAM-1 expression, but the actual expression of ICAM-1 was very much lower than 
that seen in media 1 and 10 (this reflects the results described in Section 4.2.2). 10-8M 
a-MSH (present for 24 hours or 5 days) had little or no effect on basal levels of ICAM- 
1 expression except in medium 24, where there was an increase (Table 4.4). a-MSH 
was examined for its immunomodulatory effect on TNF-a-stimulated ICAM-1 
expression in the three media (Table 4.4). No significant effects were seen in medium 
1, the mitogen rich medium. In medium 24, there was a large n-fold increase in ICAM- 
1 expression, but the basal and cytokine-stimulated levels were very low to begin with. 
In 2 out of the 3 experiments conducted in medium 10, there was an inhibitory effect, 
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Figure 4.6 The effect of 10-8M a-MSH on basal and TNF-a-stimulated 
ICAM-1 expression in medium 10. Melanocytes were cultured for 5 days in 
medium 10. Cells were treated with 10-8M a-MSH at every medium change (x3) 
over the 5 days or for the final 24 hours (as described in Table 4.4 for the 
individual experiments). 100U/ml TNF-a was added for the final 24 hours and 
basal (closed bar) and cytokine-stimulated (open bar) ICAM-1 expression was 
analysed (as described in Section 2.9). The results show the mean ICAM-1 
expression (O. D. 492-620nm/104 cells x 10-3) ± SEM of 3 experiments using 
melanocytes from different donors. 
control 10'M a. MSH (x3) 
144 
but overall this did not achieve statistical significance (Table 4.4 and Figure 4.6). 
M746P4, was initially cultured in maintenance medium A, which contained CT and this 
could have been an influence on the results seen in the three media. Certainly, in 
medium 10, the cells were unresponsive to a-MSH, unlike the M760P4 and M771P4, 
which were initially cultured in maintenance medium B. 
From this preliminary study there was a hint that a-MSH could oppose the actions of 
TNF-a. The initial culture medium may have played a role in masking the results from 
one of the donors, therefore in an attempt to standardise procedures, all further 
experiments (discussed in the following Sections 4.3.2-4.3.5) were established in 
maintenance medium C and cultured under experimental medium 23 for 5 days. 
Maintenance medium C did not contain CT and experimental medium 23, was defined 
as only containing bFGF and did not have non-physiological mitogens or 
serum/pituitary extracts which could be possible sources of POMC-peptides and 
cytokines. 
4.3.2 Effect of a-MSH and TNF-a on constitutive ICAM-1 expression in 
melanocytes cultured in a defined experimental medium. 
Melanocytes from 8 different donors were utilised in various experiments throughout 
the following Sections 4.3.2 to 4.3.5. All the cultures had been grown in maintenance 
medium C and cultured in experimental medium 23. Cells were cultured with a-MSH 
present either for the final 24 hours or throughout the 5 day experimental period. TNF- 
a was always added for the final 24 hours to the appropriate cells. 
a-MSH over a range of concentrations had little or no effect on basal ICAM-1 
expression, whether present for just 24 hours or for the full experimental period (Figure 
4.7, individual results for each melanocyte culture shown in Table 4.5a). In contrast to 
a-MSH, a significant 20 fold increase of ICAM-1 expression in response to 100U/ml 
TNF-a (p<0.01) was demonstrated (Figure 4.7). In two of these experiments, IBMX 
additionally had little or no effects on basal ICAM-1 expression (Table 4.5a) while the 
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effect of ACTH and y-MSH on basal levels were not examined in this medium because 
there was not enough cells to set up complete experiments. 
4.3.3 Effect of 10-8M a-MSH on TNF-a-stimulated ICAM-1 expression in 
melanocytes. 
ICAM-1 expression was increased in a dose dependent manner by TNF-a in 
melanocytes from 3 different donors (Figure 4.8a and Table 4.6). In all three 
experiments, 10,8M a-MSH was able to inhibit the effect of 10-500U/ml TNF-a on 
ICAM-1 expression when added for the final 24 hours. However, when cells were 
preincubated with 10-8M a-MSH the only inhibition achieved was with 100U/ml TNF- 
a. When the normalised data from the 3 experiments were combined (Table 4.6 and 
Figure 4.8b), the average degree of inhibition produced by 10-8M a-MSH (when added 
for the final 24 hours) was of the order of 50% (58% inhibition at 1OU/ml TNF-(x, 63% 
at 100U/ml TNF-a and 43% inhibition at 500U/ml TNF-a) (statistical significance was 
not achieved due to donor to donor variability). 10-8M a-MSH, when present for 5 days 
reduced 100U/ml TNF-a-stimulated ICAM-1 expression by 28% (statistical 
significance not achieved), when based on the mean of the normalised data. 
4.3.4 Effect of a-MSH on 100U/ml TNF-a-stimulated ICAM-1 expression in 
melanocytes. 
a-MSH over a range of concentrations from 10'11M to 10-8M, was able to inhibit 
ICAM-1 expression in response to 100U/ml TNF-a (Table 4.5b and Figure 4.9). The 
greatest reduction (of 55%) was seen when (x-MSH at 10'10M was present for the final 
24 hours (just failing to achieve statistical significance, p<0.0697). However, when the 
data from 8 experiments were taken into consideration, 10-8M a-MSH had a slightly 
greater inhibition of 57% (Figure 4.10 and Table 4.5b). Inhibition achieved with a- 
MSH present throughout the 5 days was not greater than that seen when a-MSH was 
present for the last 24 hours only. 
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Figure 4.8 Effects of a-MSH on TNF-a-stimulated ICAM-1 expression. 
Melanocytes were cultured in experimental medium 23 for 5 days without 
(closed triangle) or with 10-8M a-MSH added for the final 24 hours (closed 
circle) or throughout the 5 days (x3 additions) (open circle). TNF-a (lU/ml to 
500U/ml) was added for the final 24 hours before ICAM-1 expression was 
analysed (as described in Section 2.9). (a) The results for the individual 
experiments are shown in (i) for donor M741, (ii) for donor M746, and (iii) for 
donor M829 (parts of this data are also shown in Tables 4.5 and 4.6). Each 
point is the mean ICAM-1 expression (O. D. 492-620nni/well/l04 cells x 10-3) ± 
SEM of triplicate wells. The SEM are omitted for clarity but range from 0.1 to 
2.3 for (i), 0.7 to 31 for (ii) and 0.1 to 2 for (iii). ICAM-1 expression 
significantly increased by TNF-a is indicated by **=p<0.01 and ***=p<0.001 
or by '1=p<0.05 based on Student's unpaired t-test and the Mann Whitney test 
respectively. Values differing significantly from the TNF-a-stimulated values 
are indicated by e=p<0.05 and eA=p<0.01 or by w=p<0.05 based on Student's 
unpaired t-test and the Mann Whitney test respectively. (b) The mean % of 
TNF-a-stimulated ICAM-1 in response to the presence of 10-8M a-MSH for the 
final 24 hours (closed bar) or for the 5 day experimental period (open bar) is 
illustrated for the 3 experiments (illustrated in Figure 4.8a) using melanocytes 
from different donors. 
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4.3.5 Comparison of the effect of a-MSH, y-MSH, ACTH and IBMX on 100U/ml 
TNF-a-stimulated ICAM-1 expression in melanocytes. 
The effects of ACTH and y-MSH on TNF-a-stimulated ICAM-1 expression were 
compared to the effects of a-MSH to explore the possibility that all POMC-peptides 
have immunomodulatory properties. IBMX was included in the study to examine the 
possible role of the cAMP/PKA intracellular signalling system in modulating the effect. 
The preliminary data for 10-11M ACTH and 10,8M y-MSH demonstrate that they are less 
potent than a-MSH (at the respective concentrations) while 10-8M ACTH had similar 
potency to 10-8M a-MSH (Figure 4.10). IBMX at 10-3M was a more potent inhibitor of 
TNF-a-stimulated ICAM-1 expression than a-MSH and reduced TNF-a-stimulated 
ICAM-1 expression by 77% (p<0.05) and 94% (p<0.05) when present for the final 24 
hours (Figure 4.10 and Table 4.5b) and for 5 days (Table 4.5b) respectively. Unlike 
a-MSH, IBMX showed a greater reduction of TNF-a-stimulated ICAM-1 expression 
when present for the longer time period. 
The data show that all the POMC-peptides examined appear to have immunomodulatory 
activity although to varying extents. The results with IBMX indicate that the inhibition 
of TNF-a-stimulated ICAM-1 expression may be working through the cAMP 
intracellular signalling pathway. 
4.3.6 Effect of a-MSH on IFN-y-stimulated ICAM-1 expression. 
A role for a-MSH in opposing TNF-a-stimulated ICAM-1 expression has been 
demonstrated in the previous sections. The next part of the study was to examine if a- 
MSH could oppose other cytokines that modulate ICAM-1 expression. In this 
preliminary study, IFN-y, a strong modulator of ICAM-1 expression was examined. 
Melanocytes from 6 different donors were cultured in maintenance medium C and then 
under experimental medium 23 as in previous sections. Flow cytometry (as described in 
Section 2.10) was used to analyse ICAM-1 expression in response to 10-8M a-MSH 
and/or 100U/ml IFN-y (mean results illustrated in Figure 4.11). IFN-y significantly 
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Table 4.7a Influence of 10"8AI cc-, IISIH and 100U/ml IFN-y on the percentage of 
normal melanocytes expressing ICAM-1. 
% of gated cells ex pressing ! CAM-1 
Donor Control a-MSII IFN-y IFN + MSH 
M969 1.4 1.22 58.09 64.36 
M970 4.41 3.74 53.41 62.3 
M971 3.69 4.41 73.13 45.06 
M972 21.14 25.46 73.78 69.48 
M983 5.04 4.56 39.82 23.53 
M994 26.59 15.25 56.59 65.40 
Mean 10.38 9.11 59.14*** 55.02 
SEM ±4.35 ± 3.83 ±5.24 ±7.18 
Table 4.7b Influence of 104M a-AISIi and 100U/ml IFNI -y on ICA11I-1 expression 
in normal melanocytes. 
Mean fluorescence 
Donor Control a-MSH IFN-y IFN + 11MSH 
M969 0.51 038 1131 10 
M970 1.08 0.72 10.66 9.28 
M971 1.29 1.06 11.41 7.01 
M972 3.52 3.96 15.03 20.09 
M983 1.21 0.98 6.74 4.55 
M994 6.27 4.84 8.73 11.48 
Mean 2.31 1.99 10.6500 10.40 
SEM ± 0.9 ± 0.78 ± 1.14 ±2.18 
P1 melanocytes from several different donors were seeded at a mean density of 3.7 x 
105 cells/T25 flask and cultured for 5-10 days in maintenance medium C. Melanocytes 
were then cultured for a further 5 days in experimental medium 23, and for the final 24 
hours cells received fresh medium (control), 10"8M a-MSH, l00U/ml IFN-y or both. 
Cells were carefully removed with 5mM EDTA and incubated with either mouse-anti- 
human ICAM-1 antibody (IgG, PE labelled) or the appropriate mouse isotype negative 
control antibody. Flow cytometry analysis of the expression was carried out as 
described in Section 2.10. Percentage of cells expressing ICAM-1 in response to the 
treatments are illustrated in Table 4.7a, while the mean fluorescence for ICAM-1 
expression is illustrated in Table 4.7b. Mean data differing significantly from control 
in response to IFN-y are indicated as **=p<0.01 and ***=p<0.001 based on Student's t- 
test. 
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Figure 4.11 Effect of 10-8M a-MSH on 100U/ml IFN-y-stimulated ICAM-1 
expression. Melanocytes were cultured for 5 days in experimental medium 23 (as 
described for the individual experiments in Table 4.7). ICAM-1 was analysed in 
response to treatments of 10-8M a-MSH, 10OU/ml IFN-y or both (all present for the 
final 24 hours of the experimental period), by flow cytometry (as described in Section 
2.10). The % of gated cells expressing ICAM-1 (closed bar) and the mean 
fluorescence of ICAM-1 expression (open bar) are shown as the mean ± SEM of 6 
experiments using melanocytes from different donors. Significant increase in the 
expression of ICAM-1 in response to IFN-y is indicated by **=p<0.01 and 
***=p<0.001, based on Student's paired t-test. 
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increased the number of cells expressing ICAM-1 (p<0.001) and stimulated ICAM-1 
expression by 4.6 fold (p<0.01) (in agreement with results in Section 4.2.2). 10,8M a- 
MSH had no significant effects on constitutive ICAM-1 expression but was able . to 
inhibit IFN-y-stimulated ICAM-1 expression in some donor melanocytes while in others 
it enhanced IFN-y-stimulated ICAM-1 expression (Table 4.7). Overall, 10"8M a-MSH 
did not affect IFN-y-stimulated ICAM-1 expression. 
4.4 MODULATION OF MAJOR HISTOCOMPATABILITY COMPLEX (MHC) 
CLASS I AND CLASS II IN NORMAL AND VITILIGO MELANOCYTES BY 
MEDIA AND CYTOKINES. 
MHC class I and class II determine the type of T cell that a cell binds. Constitutive and 
cytokine-regulated expression of MHC class I and class II were examined in both 
normal and vitiligo melanocytes to determine their ability as potential antigen- 
presenting cells. 
4.4.1. Expression of MHC class I and class II molecules in normal melanocytes. 
The expression of MHC class I and class II molecules was examined in melanocytes 
from six different donors after being cultured in experimental media for 5 days using 
flow cytometry (as described in Section 2.10). Cytokines were added for the final 24 
hours. (Three of the cultures examined in this section were from the comparative study 
with the vitiligo melanocytes (Section 4.5.2)). 
MHC class I was generally expressed in more than 90% of melanocytes from each 
donor (Table 4.8 and Figure 4.12a-c). In response to IFN-y there was no significant 
change in the percent of cells expressing the molecules except in medium 10, where 
there was a small 1% increase (p<0.05). However, there was a significant increase in 
the intensity of fluorescence by 62% in both media 1 (Figure 4.12a) and 10 (Figure 
4.12b) (both at p<0.05) and by 41% in medium 24 (Figure 4.12c) (p<0.01). 
Melanocytes had very low constitutive expression of MHC class II molecules in all 
media examined (Figure 4.12d-I). While IFN-y was capable of increasing both the 
Table 4.8a Influence of media and IFN-y on the percentage of normal melanocytes 
expressing MHC class I. 
% of gated cells expression MHC c lass I 
Medium 1 Medium 10 Medium 24 
Donor Control IFN-y Control IFN-y Control IFN-y 
M577 98.38 92.45 97.15 98.15 98.55 93.11 
M777 95.87 96.24 ND' ND ND ND 
M746 98.49 97.24 97.87 99.15 97.82 99.41 
M813 ND ND 96.14 98.41 ND ND 
M833 99.04 98.84 96.97 98.95 ND ND 
M843 96.21 97.71 98.1 97.94 ND ND 
M741 97.28 99.29 99.34 98.79 98.69 98.78 
Mean 97.55 96.96 97.6 98.57* 98.35 97.1 
SEM ± 0.53 ± 1.01 ± 0.45 ±0.19 ± 0.27 ±2 
Table 4.8b Influence of media and IFN-y on the expression of MHC class I in 
normal melanocytes. 
Mean fluorescence 
Medium 1 Medium 10 Medium 24 
Donor Control IFN-y Control IFN-y Control IFN-y 
188.82 236.45 202.45 358.86 155.85 216.34 
M777 78.95 106.6 ND ND ND ND 
M746 64.33 102.11 80.62 147.03 57.17 103 
M813 ND ND 84.7 142.29 ND ND 
M833 111.31 248.61 92.18 142.66 ND ND 
M843 63.35 184.36 72.23 135.23 ND ND 
M741 92.78 95.73 115.31 120.1 173.11 226.19 
Mean 99.9 162.31* 107.92 174.41* 128.71 181.84** 
SEM ± 19.26 ± 28.63 ± 19.83 ± 37.1 ± 36.12 ± 39.52 
Table 4.8c Influence of IFN-y on the expression of MHC class I in vitiligo 
melanocytes. 
% Cells expressing MHC class I Mean fluorescence 
Donor Control IFN-y Control IFN- 
VM2 (M813) 96.22 97.22 43.38 94.7 
VM4 (M843) 95.18 96.63 75.32 86.49 
VMS (M833) 99.14 99.41 93.7 177.79 
Mean 96.85 97.75 70.8 119.66 
SEM ±1.19 ±0.85 ±14.7 ±29.16 
Mean 97.07 98.43 83.04 140.06** 
SEM ±0.57 ±0.29 ±5.82 ±2.42 
Table 4.8: P4 normal and vitiligo melanocytes from several different donors were 
plated at 0.66 to 3.39 x 105 per T25 flask in maintenance medium B or C and allowed to 
adhere for 24 hours. Cells were then cultured for a further 5 days in experimental media 
1,10 or 24 (in Table 4.8c cells were only cultured in experimental medium 10). 
100U/ml IFN-y was added for the final 24 hours. Cells were gently trypsinized at the 
end of the experimental period and incubated with either mouse anti-human HLA- 
A, B, C antibody (IgG2a) to detect MHC class I expression or the appropriate mouse 
isotype negative control antibody. Flow cytometry analysis of the expression was 
carried out as described in Section 2.10. Table 4.8a illustrates the percentage of cells 
gated expressing MHC class I for normal melanocytes while Table 4.8b illustrates the 
mean fluorescence for MHC class I expression for normal melanocytes. Table 4.8c 
illustrates the results of both parameters for the vitiligo melanocytes. The meanb data 
for the paired normal cultures (cultures indicated in the brackets and data for these 
shown in Tables 4.8a-b) are also illustrated in this table for ease of comparison. Mean 
data differing significantly from control in response to IFN-y are indicated as * p<0.05, 
and **=p<0.01 based on Student's t-test. 
a ND = not done. 
Figure 4.12 Effect of IFN-y on the expression of MHC class I and MHC class II in 
normal melanocytes. Melanocytes were cultured for 5 days under the experimental 
media 1 (a and d), 10 (b and e) or media 24 (c and f). 100U/ml IFN-y was added for 
the final 24 hours and then MHC class I (a-c) and MHC class II (d-f) expression were 
examined using flow cytometry (as described Section 2.10). The % of gated cells 
expressing the two surface molecules (closed bar) and the mean fluorescence (open bar) 
are illustrated as the mean ± SEM of 3-6 experiments using melanocytes from different 
donors. Significant increase on the expression of MHC class I and class II in response 
to IFN-y are indicated by *=p<0.05 and ** p<0.01 based on Student's paired t-test. . 
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number of cells expressing the molecule and intensity of fluorescence, statistical 
significance was not achieved under all media conditions due to large donor to donor 
variability (Table 4.9). The number of cells expressing MHC class II were significantly 
increased 31 fold in medium 1 (p<0.01) (Figure 4.12d) and 48 fold in medium 10 
(p<0.05) (Figure 4.12e). The intensity of expression was significantly increased 16 fold 
in medium 1 (p<0.01) (Figure 4.12d). 
The expression of MHC class I and class II in donor melanocytes M777 was examined 
in medium 1, in response to IFN-y, TNF-a and IL-1a. Both IFN-y (Figure 4.13b) and 
TNF-a (Figure 4.13c) increased MHC class I expression by 35% and 40% respectively 
in comparison to the control (Figure 4.13a) while IL-la reduced the expression slightly 
by 15% (Figure 4.13d) (all values based an the mean fluorescence corrected for isotype 
staining). IFN-y (Figure 4.13f and Table 4.9b) increased MHC class II expression in 
comparison to the control (Figure 4.13e and Table 4.9b) whereas TNF-a and IL-la 
(Figures 4.13g and 4.13h respectively) had no effects on MHC class II expression. 
The majority of melanocytes in any donor population expressed MHC class I at a high 
level while there was low constitutive expression of MHC class II. IFN-y was 
influential in stimulating increased expression of MHC class I and MHC class II. 
4.4.2. Comparison of MHC class I and class II molecule expression in normal and 
vitiligo melanocytes. 
Normal and vitiligo melanocytes constitutively expressed MHC class I surface 
molecules in medium 10 (Table 4.8 and Figure 4.14). While IFN-y did not alter the 
number of melanocytes expressing the MHC class I molecules, the mean fluorescence 
was increased by 69% in both normal (p<0.01) and vitiligo melanocytes. 
Constitutive expression of the MHC class II was minimal in both normal and vitiligo 
melanocytes. IFN-y significantly increased the number of vitiligo melanocytes 
expressing the antigen (p<0.05), with an associated increase of 15.86 mean fluorescence 
Table 4.9a Influence of media and IFN-y on the percentage of normal melanocytes 
expressing MHC class II. 
% of gated cells expression MHC cl ass II 
Medium 1 Medium 10 Medium 24 
Donor Control IFN-y Control IFN-y Control IFN-y 
M577 11.93 68.47 3.07 92.61 3.49 37.2 
M741 -0.52 64.69 0.1 60.41 0.39 12.68 
M746 0.14 38.2 0.26 -0.06 0.16 0.13 
M777 -0.21 70.61 ND' ND ND ND 
M813 ND ND -1.93 31.77 ND ND 
M833 0.33 89.2 2.3 69.71 ND ND 
M843 -0.25 17.29 -0.2 2.76 ND ND 
Mean 1.9 58.08** 0.89 42.87* 1.35 16.67 
SEM ± 2.01 ± 10.55 ± 0.58 ± 15.36 ± 1.07 ± 10.89 
Table 4.9b Influence of media and IFN-y on the expression of AIHC class II in 
normal melanocytes. 
Mean fluorescence 
Medium 1 Medium 10 Medium 24 
Donor Control IFN-y Control IFN-y Control IFN-y 
20.28 89.16 2.52 179.75 6.19 18.93 
M741 -2.67 38.13 -1.75 37.7 -0.82 7.86 
M746 -0.56 20.96 0.09 -0.93 -0.11 -0.8 
M777 -0.15 34.1 ND ND ND ND 
M813 ND ND -0.08 10.35 ND ND 
M833 0.74 65.2 1.7 28.98 ND ND 
M843 -2.69 2.37 -2.61 0.51 ND ND 
Mean 2.68 41.65** -0.02 44.39 1.75 8.66 
SEM ± 3.58 f 12.72 ± 0.8 ± 28.01 ± 2.23 ± 5.71 
Table 4.9c Influence of IFN-y on the expression of MHC class II in vitiligo 
melanocytes. 
% Cells expressing MHC class II Mean fluorescence 
Donor Control IFN-y Control IFN-y 
VM2 (M813) 1.68 55.79 1.62 21.19 
VM4 (M843) -0.12 27.1 -1.65 9.29 
VMS (M833) 2.16 51.41 1.34 18.41 
Mean 1.24 44.78* 0.44 16.30* 
SEM ±0.69 ±9 11.05 ±3.59 
Mean 0.06 34.77 -0.33 13.29 
SEM ±1.23 ±19.38 ±1.25 ±8.34 
Table 4.9: P4 normal and vitiligo melanocytes from several different donors were 
plated at 0.66 to 3.39 x 105 cells/T25 flask in maintenance media B or C and allowed'to 
adhere for 24 hours. Cells were then cultured for a further 5 days in experimental media 
1,10 or 24 (in Table 4.9c cells were only cultured in experimental medium 10). 
100U/ml IFN-y was added for the final 24 hours. Cells were gently trypsinized at the 
end of the experimental period and incubated with either mouse anti-human HLA- 
DR, DP, DQ antibody (IgGI) to detect MHC class II expression or the appropriate mouse 
isotype negative control antibody. Flow cytometry analysis of the expression was 
carried out as described in Section 2.10. Table 4.9a illustrates the percent of cells gated 
expressing MHC class II for normal melanocytes while Table 4.9b illustrates the mean 
fluorescence for MHC class II expression in normal melanocytes. Table 4.9c illustrates 
the results of both parameters for the vitiligo melanocytes. The mean data for the 
paired normal cultures (cultures indicated in the brackets and data for these shown in 
Tables 4.9a-b) are also illustrated in this table for ease of comparison. Mean data 
differing significantly from control in response to IFN-y are indicated as *=p<0.05 and 
**=p<0.01 based on Student's paired t-test. 
a ND = not done. 
Figure 4.13 Effect of IFN-y, TNF-a and IL-la on the expression of AlHC class I 
and class II in normal melanocytes. Melanocytes from donor M777, were cultured 
for 5 days under the experimental medium 1 (as described in Tables 4.8 and 4.9). Cells 
were untreated (a and e) or treated with 100U/ml IFN-y (b and f), l00U/ml TNF-a (c 
and g) or 100U/ml IL-la (d and h) for the final 24 hours before MHC class I (a-d) and 
MHC class II (e-h) expression were examined using flow cytometry (as described in 
Section 2.10). All figures show isotype fluorescence (dashed line) and MHC class I or 
MHC class II fluorescence (solid line). 
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Figure 4.14 Effect of IFN-y on the expression of MHC class I and class II in 
normal and vitiligo melanocytes. Normal (a and c) and vitiligo (b and d) 
melanocytes were cultured for 5 days under experimental media 10 (as described in 
Tables 4.8 and 4.9 for the individual experiments). 100U/ml IFN-y was added for 
the final 24 hours and then MHC class I (a and b) and class II (c and d) expression 
was examined using flow cytometry (as described in Section 2.10). The % of gated 
cells expressing the two surface molecules (closed bar) and the mean fluorescence 
(open bar) are illustrated as the mean ± SEM of 3 experiments using melanocytes 
from 3 different normal subjects and 3 different vitiligo patients. Significant 
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increase in the expression of MHC class I and MHC class II in response to IFN-y are 
indicated by *=p<0.05 and **=p<0.01 based on Student's paired t-test. 
* 
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(37 fold, p<0.05). A non-significant increase was seen in normal melanocytes for both 
parameters. 
The effect of IFN-y and LCM on MHC class I and class II expression in medium 1 was 
examined in donor melanocytes M833 and VM5 (Figure 4.15). IFN-y increased MHC 
class I expression by 123% in M833 (Figure 4.15b) and by 120% in VM5 (Figure 
4.15h), while LCM increased the expression of MHC class I by 226% in M833 (Figure 
4.15c) and by 213% in VM5 (Figure 4.15i). ' The expression of MHC class II was 
increased by 88 fold in response to IFN-y (Figure 4.15e) and by 149 fold in response . to 
LCM (Figure 4.15f) in M833 while in VM5 the expression of MHC class II was 
increased by 182 fold in response to IFN-y (Figure 4.15k) and by 373 fold in response 
to LCM (Figure 4.151). 
The effect of TNF-a on MHC class I and class II expression in comparison to IFN-y 
was examined in donor melanocytes M843 and VM4 (Figure 4.16). The expression of 
MHC class I in medium 10 was not influenced by TNF-a in M843 (only 10% increase, 
Figure 4.16c), but in VM4, TNF-a increased MHC class I expression by 89% (Figure 
4.16i), whereas IFN-y increased MHC class I expression by 87% in M843 (Figure 
4.16b) and by 118% in VM4 (Figure 4.16h). However, as only one experiment was 
performed using this cytokine, firm conclusions cannot be drawn from these results. 
TNF-a) had no influence on the expression of MHC class II in M843 (Figure 4.16f) or -- 
VM4 (Figure 4.161) (this result is similar to what was seen with M777 in Section 4.4.1) 
whereas IFN-y increased MHC class II expression in VM4 (Figure 4.16k and Table 
4.9c). 
There were no significant differences in the expression of MHC class I and class II 
between normal and vitiligo melanocytes. The increase of both MHC class I and class 
II expression by IFN-y was very similar. 
Figure 4.15 Effect of IFN-y and T lymphocyte conditioned medium (LCM) on the 
expression of MHC class I and class II in normal and vitiligo melanocytes. P4 
normal and vitiligo melanocytes from donors M833 (a-f) and VM5 (g-1) respectively 
were cultured for 5 days under the experimental medium 1 (as described in Tables 4.8 
and 4.9). Cell were untreated (a, d, g, and j) or treated with 100U/ml IFN-y (b, e, h, 
and k) or 25% LCM (c, f, i, and 1) for the final 24 hours before MHC class I (a-c and g- 
h) and MHC class II (d-f and j-l) expression were examined using flow cytometry (as 
described in Section 2.10). All figures show isotype fluorescence (dashed line) and 
MHC class I or MHC class II fluorescence (solid line). 
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Figure 4.16 Effect of IFN-y and TNF-a on the expression of MHC class I and class 
II in normal and vitiligo melanocytes. Normal and vitiligo melanocytes from donors 
M843 (a-f) and VM4 (g-1) respectively were cultured for 5 days under the experimental 
medium 10 (as described in Tables 4.8 and 4.9). Cell were untreated (a, d, g, and j) or 
treated with 100U/ml IFN-y (b, e, h, and k) or with 100U/ml TNF-a (c, f, i, and 1) for 
the final 24 hours before MHC class I (a-c and g-h) and MHC class II (d-f and j-1) 
expression were examined using flow cytometry (as described in Section 2.10). All 
figures show isotype fluorescence (dashed line) and MHC class I or MHC class II 
fluorescence (solid line). 
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4.5 EXPRESSION OF LFA-3 (CD58) AND CD40 ON NORMAL 
MELANOCYTES. 
LFA-3 and CD40 are additional cell surface molecules that are thought to play a role in 
the binding and activation of T cells. 
4.5.1 Effect of media and cytokines on the expression of LFA-3 in normal 
melanocytes. 
Melanocytes were cultured under experimental medium 23 for 5 days and LFA-3 
expression was analysed by flow cytometry in response to IFN-y and TNF-a. In this 
medium, 70% (mean value) of melanocytes from each donor expressed LFA-3 
constitutively (see Table 4.10 for individual experiments) with a mean fluorescence of 
10. Both IFN-y and TNF-a significantly increased the number of cells expressing LFA- 
3 by 3% and 6% respectively (Figure 4.17) but these were very small increases and the 
mean fluorescence was not significantly altered. 
One melanocyte donor (M970) was cultured under 3 different experimental media for 5 
days (1,23 and 24) to examine the expression of LFA-3 in response to media 
components. Cells cultured in medium 1 had the highest level of LFA-3 expression 
with 95% of cells gated expressing LFA-3 (mean fluorescence was 17, Figure 4.18a). 
Cells cultured in medium 23, had the intermediary levels of expression (76% of cells 
gated expressed LFA-3 at a mean fluorescence of 11, Figure 4.18b and Table 4.10), 
while medium 24 had the lowest level of LFA-3 expression with 53% of cells gated 
expressing LFA-3 (mean fluorescence was 9, Figure 4.18c). IFN-y had no influence on 
the mean fluorescence levels in these three media (Figures 4.18d-f). 
LFA-3 expression on melanocytes was constitutively high and this was affected by 
media composition but was not affected by cytokines. 
Table 4.10a Influence of IFN-y and TNF-a on the number of cells expressing LFA- 
3. 
%o f gated cells expressing LFA-3 
Donor Control IFN-y TNF-a 
M969 70.84 74.87 75.69 
M970 76.99 75.83 ND 
M971 85.49 87.18 88.1 
M972 63.77 67.05 ND 
M983 52.68 56.84 59.05 
Mean 69.95 72.35* 74.28* 
SEM ± 5.61 ± 5.04 ±8.42 
Table 4.10b Influence of IFN-y and TNF-a on the expression of LFA-3 in normal 
melanocytes. 
Mean fluorescence 
Donor Control IFN-y TNF-a 
M969 10.75 13.99 12.51 
M970 10.9 10.7 ND' 
M971 11.68 12.51 12.41 
M972 8.16 10.62 ND 
M983 8.68 8.62 11.9 
Mean 10.03 11.29 12.27 
SEM ± 0.68 ±0.91 ±0.19 
P1 melanocytes from several different donors were seeded at a mean density of 3.7 x 
105 cells/T25 flask and cultured for 5-10 days in maintenance medium C. Melanocytes 
were then cultured for a further 5 days in experimental medium 23, and for the final 24 
hours cells received fresh medium (control), 100U/ml IFN-y or 100U/ml TNF-a. Cells 
were carefully removed with 5mM EDTA and incubated with either mouse-anti-human 
LFA-3 antibody (IgG2a FITC labelled) or the appropriate mouse isotype negative control 
antibody. Flow cytometry analysis of the expression was carried out as described in 
Section 2.10. Percentage of cells expressing LFA-3 in response to the treatments are 
illustrated in Table 4.10a, while the mean fluorescence for LFA-3 expression is 
illustrated in Table 4.10b. Mean data differing significantly from control in response to 
IFN-y or TNF-a are indicated as *=p<0.05 based on Student's t-test. 
a ND - not done. 
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Figure 4.17 Effect of cytokines, IFN-y and TNF-a on the expression of LFA-3 in 
normal melanocytes. Melanocytes were cultured for 5 days in experimental 
medium 23 and treated for the final 24 hours with 100U/ml IFN-y or 100U/ml TNF- 
a (as described in Table 4.10 for individual experiments). LFA-3 expression was 
analysed by flow cytometry (as described in Section 2.10). The % of cells gated to 
express LFA-3 (closed bar) and the mean fluorescence for LFA-3 expression (open 
bar) are illustrated as the mean ± SEM of 3-5 experiments using melanocytes from 
different donors. Significant increases in the number of cells that express LFA-3 in 
response to cytokines are indicated as *=p<0.05 based on Student's paired t-test. 
Figure 4.18 Effect of IFN-y and media on the expression of LFA-3 in normal 
melanocytes. Melanocyte from donor M1044, were cultured in experimental media 1 
(a and d), 23 (b and e) or 24 (c and f) for 5 days. Cells were untreated (a-c) or treated 
for the final 24 hours with 100U/ml IFN-y (d-f) and LFA-3 expression analysed by flow 
cytometry (as described in Table 4.10 and Section 2.10). All figures show isotype 
fluorescence (dashed line) and LFA-3 antibody fluorescence (solid line). The mean 
fluorescence was 17 (medium 1), 11 (medium 23) and 9 (medium 24) for untreated cells 
while the mean fluorescence was 15 (medium 1), 11 (medium 23) and 8 (medium 24) 
for cells treated with IFN-y. 
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Table 4.11a Influence of media and IFN-y on the number of normal melanocytes 
expressing CD40. 
gated cells expressing CD40 
Medium I Medium 10 Medium 24 
Control IFN-y Control IFN-y Control IFN_ 
M577 2.68 3.95 4.08 4.1 4.73 5.39 
M741 -0.46 -0.1 0.07 0.19 0.38 1.45 
M746 -0.04 -0.03 -0.07 -0.07 0.01 -0.02 
M777 -0.11 0.32 ND' ND ND ND 
M829 0.52 0.56 0.04 0.36 0.79 0.2 
Mean 0.52 0.89 0.87 1.15 1.48 1.76 
SEM ± 0.56 ± 0.78 ± 1.08 ± 0.99 ± 1.1 ± 1.25 
Table 4.11b Influence of media and IFN-y on the expression of CD40 on normal 
melanocytes. 
Mean fluorescence 
Medium 1 Medium 10 Medium 24 
Control IFN-y Control IFN-y IFN-y 
M577 0.93 2.25 2.69 1.64 2.04 1.85 
M741 -0.47 0.14 0.3 0.25 0.97 1.8 
M746 -0.76 -0.38 -0.02 -0.32 0.05 -0.09 
M777 0.58 0.56 ND ND ND ND 
M829 0.87 0.39 0.32 0.24 0.43 -0.22 
Mean 0.23 0.59 0.83 0.45 0.87 0.88 
SEM ± 0.35 ± 0.44 ± 0.62 ± 0.42 ± 0.43 ±0.55 
P4 melanocytes from 5 different donors were plated at 2 to 2.89 x 105 cells/T25 flask in 
maintenance media B or C, and allowed to adhere for 24 hours before being cultured for 
5 days in experimental media 1,10 or 24.100U/ml IFN-y was added for the final 24 
hours. At the end of the experimental period cells were gently trypsinized and 
incubated with either mouse anti-human CD40 antibody (IgGI) or the appropriate 
mouse isotype negative control antibody (described in Section 2.10) before flow 
cytometry analysis was carried out. Percentage of cells gated expressing CD40 are 
shown in Table 4. lla (104 cells were analysed), while the mean fluorescence for the 
gated cells corrected for isotype fluorescence is shown in Table 4. llb. 
a ND = not done. 
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4.5.2 Effect of IFN-y on the expression of CD40 on normal melanocytes. 
Melanocytes cultured in experimental media 1,10 or 24 for 5 days were examined for 
CD40 expression by flow cytometry. There was much donor-to-donor varation (Table 
4.11) but overall the basal expression of CD40 was very low. Media and IFN-y did not 
influence the expression of CD40 (Figure 4.19). 
4.6 T CELL BINDING TO NORMAL HUMAN MELANOCYTES. 
The ability of any cell to express immune surface molecules usually indicates their 
ability to bind and activate T cells. In this preliminary study an ELISA method was 
used to detect the ability of T cells to bind to unstimulated and cytokine-stimulated 
melanocytes. The methodology used is well established in this laboratory for T 
lymphocyte binding to keratinocytes. 
Three experiments were performed using melanocytes from different donors for each 
experiment. In the first experiment, the cells were cultured in 12 wells and the coloured 
endpoint product transferred to 96 well plates for O. D. readings, while in the other two 
experiments melanocytes were cultured in 96 well plates. The individual results are 
shown in Table 4.12 while the mean data for control and IFN-y-treated cells cultured in 
media 1 and 10 are shown in Figure 4.20. Although it is preferable to correct 
parameters for cell number (or protein for example), the data were not corrected in these 
experiments as cytokines do not have a significant effect on melanocyte proliferation. 
Additionally, the cell number plates set up for M767 were ruined in storage. 
In all three experiments, T cells did bind to untreated melanocytes. However, T cells 
were also bound to the tissue culture plastic, where melanocytes had washed away due 
to changes in temperature during the ELISA method. The overall results in response to 
cytokines were disappointing (Figure 4.20), with considerable donor-to-donor variation 
being apparent (see Table 4.13). M760 were unresponsive to cytokine stimulation 
while, in the other two experiments, some increases in T cell binding were seen in 
response to cytokine stimulation. 
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Figure 4.19 Effect of IFN-y on the expression of CD40 in normal melanocytes. 
Melanocytes were cultured for 5 days under the experimental media 1 (a), 10 (b) or 24 
(c) (as described in Table 4.11 for the individual experiments) . 
100U/ml IFN-y was 
added for the final 24 hours and then CD40 expression was analysed using flow 
cytometry (as described in Section 2.10). The % of gated cells expressing CD40 
(closed bar) and the mean fluorescence of CD40 expression (open bar) are illustrated as 
the mean ± SEM of 4-5 experiments using melanocytes from different donors. 
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Figure 4.20 Effect of IFN-y on normal melanocyte/T cells interactions. 
Melanocytes were cultured for 5 days under experimental media conditions 1 and 10 
(as described in Table 4.13). Cell were untreated (closed bar) or treated with 
100U/ml IFN-y (open bar) for the final 24 hours. Freshly isolated T cells (as 
described in Section 2.11.1) were added to the melanocytes at the concentrations 
indicated in Table 4.12 and T cell binding was analysed by an ELISA method (as 
described in Section 2.11.3). The data represents the mean T cell binding (O. D. 492- 
620nm/well) ± SEM of 3 experiments using melanocytes from different donors. 
medium I medium 10 
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4.7 DISCUSSION. 
The etiology of vitiligo remains unclear. Several hypotheses exist e. g. neuronal, 
autoimmune and an inherent melanocyte defect to explain the possible cause of vitiligo 
as discussed in Section 1.4. An immune component has been implicated in vitiligo 
(Section 1.4.3), but it still remains to be determined whether this is the primary defect 
or a secondary response to damage caused by other mechanisms. Melanocytes are 
capable of antigen presentation (Le Poole et al, 1993b) and the present study examined 
whether normal and vitiligo melanocytes would differ in their constitutive expression of 
immune-related molecules or in their response to cytokines which induce their 
expression. Additionally, an interesting theory has arisen suggesting the involvement of 
MSH-related peptides in the pathogenesis of vitiligo (Liu et al, 1995). 
Recent data showing that the melanotropins are produced by cells of the epidermis and 
dermis (Thody et al, 1983; Farooqui et al, 1993; Schauer et al, 1994; Iyengar, 1995; 
Kippenberger et al, 1995; Slominski et al, 1995; Chakraborty et al, 1996; Slominski et 
al, 1995; Wintzen et al, 1996; Teofoli et al, 1997; Wakamatsu et al, 1997; Can et al, 
1998), and that their production increases following UV exposure suggest a 
paracrine/autocrine role for these peptides in skin (recently reviewed by Luger et al, 
1997; Luger, 1998). MC1R are present on human melanocytes (Donatien et al, 1992; 
De Luca et al, 1993; Thody et al, 1993; Suzuki et al, 1996), immortalized (Chakraborty 
& Pawelek, 1993) and normal keratinocytes (Bhardwaj et al, 1996) and human 
endothelial cells (Hartmeyer et al, 1997). Additionally many immunocompetent cells 
express MC1R including murine macrophages (Star et al, 1995), human neutrophils 
(Catania et al, 1996) and human monocytes (Rajora et al, 1996; Bhardwaj et al, 1997). 
Several groups now report on the polymorphic nature of the human MC1R gene 
(Valverde et al, 1995 & 1996a; Box et al, 1997; Koppula et al, 1997; Ichii-Jones et al, 
1998; Smith et al, 1998). Red haired individuals who tan poorly and who commonly 
suffer skin inflammation on UV exposure exhibit a variety of MC1R variants (Valverde 
et al, 1995). They also have a susceptibility to melanoma and one variant of the MCIR 
has been associated with melanoma (Valverde et al, 1996a). In contrast to the work by 
Valverde and co-workers, Ichii-Jones et al. (1998) report that the polymorphic nature of 
the human MC1R does not appear to relate to skin type determination or predisposing 
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an individual to melanoma development. Recently, the Argl51Cys variant, which is 
associated with red haired fair skinned individuals, was found to be non-functional, as 
cAMP production was not stimulated when NDP-MSH was bound (Frändberg et al, 
1998). An alteration in the sensitivity of the MC1R may play a role in the development 
of vitiligo (Liu et al, 1995). Pigment synthesis in response to UV is relatively complex; 
melanin precursors and intermediates are formed into a range of coloured and colourless 
hydroxyindoles and some forms of pigment production represent a greater risk for the 
melanocyte in terms of cytotoxicity (Urabe et al, 1994). Following UV irradiation, the 
skin produces a wide range of cytokines, many of which will upregulate adhesion 
molecule expression on melanocytes (e. g. Yohn et al, 1990; Kirnbauer et al, 1992; 
Krasagakis et al, 1995). The combination of increased pigmentation and UV/cytokine- 
induced upregulation of adhesion molecules on melanocytes might make these cells a 
target for infiltrating T cells. As a-MSH has many biological activities, it was 
speculated that in human melanocytes, in addition to its role as a stimulator of 
pigmentation (Hunt et al, 1994a, b&c; Abdel-Malek et al, 1995; McLeod et al, 1995; 
Maeda et al, 1996; Suzuki et al, 1996), a-MSH may prevent the melanocyte from 
becoming a premature target for the immune system. a-MSH was recently implicated 
in modulating pigmentary responses following UVB irradiation (Im et al, 1998) and 
ADF, an antioxidant was capable of increasing MC1R expression and the binding of 
NDP-MSH to the receptor (Funasaka & Ichihashi, 1997), in a similar manner to UVB 
(Funasaka & Ichihashi, 1997; Funasaka et al, 1998). 
The data in this chapter demonstrated that both normal and vitiligo melanocytes were 
capable of expressing ICAM-1, MHC class I and class II either constitutively or in 
response to cytokines. However, there was no significant difference in expression 
between normal and vitiligo melanocytes once these cells were established in culture. 
This is the first study, to the best of my knowledge, to demonstrate that cultured vitiligo 
melanocytes express these surface molecules and that the level of expression is 
enhanced in response to cytokines in a manner comparable to normal melanocytes. 
Integrin expression has also been shown to be similar on normal and vitiligo cultured 
melanocytes and in biopsies from control, non-lesional, perilesional and lesional skin 
(Le Poole et al, 1997). Firm evidence is provided to illustrate that a-MSH opposed the 
actions of TNF-a on the expression of ICAM-1 in normal melanocytes. 
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The observation that a-MSH could reduce TNF-a-stimulated ICAM-1 expression in 
human melanocytes was first reported in brief by Hewitt et al. (1993). Additionally, in 
both a macrophage-like cell line (Luger et al, 1993) and monocytes (Köck et al, 1991), 
a-MSH has been reported to reduce IFN-y-enhanced MHC class I molecule expression 
although MHC class II and ICAM-1 were unaffected in monocytes (Köck et al, 1991). 
ICAM-1 is involved in T cell activation, hence a decrease in ICAM-1 expression may 
reduce the likelihood of T cell activation. However, other adhesion molecules are also 
involved in T cell binding, such as MHC class I and class II (which determine whether 
CD8 or CD4 T cells bind respectively) and activation. These also need to be considered 
in this context and studies with a-MSH and related peptides will need to be extended 
accordingly. A preliminary study indicated that melanocytes could bind T cells as 
previously reported (Nickoloff et al, 1991; Le Poole et al, 1993b) but the results were 
not convincing due to problems with the technicalities of the assay employed (Section 
4.6). 
Both normal and vitiligo melanocytes had low constitutive expression of ICAM-1 under 
all conditions examined and responded to cytokines with increased expression (Figures 
4.1-4.3 and 4.5). The effect of various cytokines on ICAM-1 expression on normal 
neonatal melanocytes has been reported previously by several groups (Yohn et al, 1990; 
Krasagakis et al, 1991; Kirnbauer et al, 1992; Le Poole et al, 1993b; Krasagakis et al, 
1995). In the current study, adult non-foreskin melanocytes were used. In this study it 
was found that UVB did not affect constitutive melanocyte ICAM-1 expression 
following 1,4 and 7 doses of 143mJ/cm2 (Figure 4.4). UVB slightly enhanced IFN-y- 
stimulated ICAM-1 response. Kirnbauer et al. (1992) showed that one dose of 
100mJ/cm2 did not alter constitutive ICAM-1 expression on normal and melanoma cells 
after 16 hours and that cytokine (IL-6, TNF-a and -ß, and IFN-y)-stimulated ICAM-1 
expresssion was suppressed. However if the melanocytic cells were analysed 72 hours 
later, constitutive ICAM-1 was significantly enhanced. This increase in ICAM-1 was 
probably due to the production of cytokines by melanocytes (Swope et al, 1994). 
The level of ICAM-1 expression in response to cytokines was greatly increased in more 
mitogenic media i. e. medium 1 (containing PMA, CT, FCS and BPE) and medium 10 
(containing FCS and BPE). This suggests a role for FCS and/or BPE rather than PMA 
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or CT in cytokine-stimulated ICAM-1 expression. Kirnbauer et al. (1992) and 
Krasagakis et al. (1991 & 1995) demonstrated ICAM-1 expression in melanocytes 
cultured in mitogen-rich medium, while Yohn et al. (1990) used melanocytes cultured 
in mitogen poor conditions for several days prior to ICAM-1 analysis. PMA was shown 
to increase cytokine-stimulated ICAM-1 expression (Yohn et al, 1990), while basal 
expression of ICAM-1 was unaffected (Yohn et al, 1990; Danen et al, 1996) or reduced 
by PMA (Krasagakis et al, 1993). PMA alone did not increase constitutive ICAM-1 
expression in normal melanocytes (Figure 4.3, medium 21). Smit et al. (1993) showed 
that constitutive ICAM-1 expression in melanocytes increased with their passage 
number when cultured under mitogen rich conditions. 
The extent of the ICAM-1 immunomodulation by a-MSH in a very defined melanocyte 
medium (medium 23 containing one sole mitogen bFGF), averaged around 50% for 
normal human melanocytes (Figure 4.8b). This phenomenon was also seen in a range 
of human melanoma cell lines and those melanoma cells with the higher number of 
MSH receptors were most susceptible to immunomodulation by a-MSH (receptor 
number not investigated on normal melanocytes) (Morandini et al, 1998). Whatever the 
extent of the inhibition, the maximal response to a-MSH was always achieved by 10-8M 
a-MSH and indeed, in normal human melanocytes, 10-11M a-MSH was sometimes 
sufficient to produce a significant inhibition in the expression of ICAM-1 (Figures 4.9- 
4.10). The inhibitory effect of a-MSH evident at 24 hours was not improved by longer 
exposure to a-MSH. Indeed, 5 days exposure to a-MSH was often less effective than 
24 hour exposure (Figures 4.8-4.9). At present this is difficult to explain except that 
MCI receptors are downregulated. IBMX was able to mimic the effects of a-MSH and 
proved to have a greater degree of inhibition (Figure 4.10) and forskolin had the same 
effect in melanoma cells (Morandini et al, 1998). This suggested that the inhibition of 
the response to TNF-a by a-MSH was via the expected cAMP dependent protein kinase 
pathway. Interestingly, a-MSH was unable to oppose the actions of IFN-y (Figure 
4.11) but cAMP elevating agents could do so in melanoma cells (Morandini et al, 1997). 
As IFN-y is generally a more potent cytokine than TNF-a, a-MSH may not be able to 
oppose the effects of IFN-y whereas cAMP modulating agents can. However, IFN-y 
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may be affecting the binding of a-MSH to the MC1R, whereas the cAMP modulating 
agents would be working post receptor. This requires further investigation. 
Morandini et al. (1998) demonstrated that the expression of ICAM-1 was modulated at 
the molecular level in melanoma cells but the expression of the ICAM-1 gene was not 
examined in cutaneous melanocytes. Recent work from this laboratory has shown that 
a-MSH will oppose TNF-a -stimulated activation of nuclear factor kappa B (NFiB), a 
transcription factor for many genes including ICAM-1 in ocular melanocytes and ocular 
and cutaneous melanoma cells (Haycock et al, 1998a & b). Additionally, a-MSH has 
been found to oppose the IL-lß induction of NFKB in keratinocytes (Brzoska et al, 
1998) and to reduce the endotoxin activation of NFKB in endothelial cells (Kalden et al, 
1998). In addition to these molecular effects, a-MSH may be invoking both normal and 
transformed melanocytes to shed ICAM-1 molecules. Melanoma cells are known to 
shed ICAM-1 molecules in a soluble form (e. g. Kageshita et al, 1993; Nakayama et al, 
1996) and this would also contribute to the evasion of immune surveillance. However, 
this was not examined in the present study. 
ICAM-1 is only one cell surface adhesion molecule involved in the binding and 
activation of T cells. Other cell surface molecules involved include MHC class I and 
class II molecules, LFA-3, B7 and CD40. The current data show that both normal and 
vitiligo melanocytes exhibit a high basal expression of MHC class I molecules (Figure 
4.12a-c and Figure 4.14a-b) as reported by other groups for normal melanocytes 
(Tsujisaki et al, 1987; Krasagakis et al, 1991 & 1993; Smit et al, 1993; Marincola et al, 
1994; Krasagakis et al. 1995). Krasagakis et al. (1993) suggested that this basal 
expression of MHC class I was in response to PMA, and that prolonged expression of 
MHC class I molecules lasted up to 2 weeks after the removal of PMA. The intensity of 
MHC class I expression was increased in response to IFN-y (Figure 4.12a-c and Figure 
4.14a-b), as previously reported (Krasagakis et al, 1991; Marincola et al, 1994). 
Marincola et al. (1994) demonstrated that HLA-A molecules were already expressed at 
a high level and remained unchanged when cells were treated with IFN-y, but that fewer 
cells expressed HLA-B molecules, and that the number of cells expressing these 
increased as did the intensity of expression in response to IFN-y. Krasagakis et al. 
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(1995) also saw increased MHC class I expression in response to the cytokines TNF-a, 
IL-1a and IL-lß. TNF-a and LCM increased the intensity of MHC class I expression 
on normal and vitiligo melanocytes (Figure 4.13 and Figures 4.15-4.16). 
The literature concerning MHC class I expression on melanocytes in vivo is unresolved. 
It has been reported as being absent (Bronstein et al, 1983), not determined/interpretable 
(Harrist et al, 1983; Natali et al, 1984) or moderately expressed (van Duinen et al, 
1984). A recent study by Moseley et al. (1997) concluded, from examining the 
pilosebaceous adnexal unit which is low in keratinocytes MHC class I expression, that, 
in vivo, melanocytes do not constitutively express MHC class I. This would not appear 
to be exceptional in that many other cell types, including central nervous system 
neurones, do not express MHC class I (Fleming et al, 1981; Daar et al, 1984; Natali et 
al, 1984). 
MHC class II expression was minimal or absent in both normal and vitiligo melanocytes 
although Smit et al. (1993) found that high passage melanocytes started to express 
MHC class II. IFN-y induced MHC class II expression in both normal and vitiligo 
melanocytes (Figures 4.12d-f and 4.14c-d) as has previously been reported for normal 
melanocytes (Houghton et al, 1984; Herlyn et al, 1987; Tsujisaki et al, 1987; 
Krasagakis et al, 1991; Le Poole et al, 1993b). TNF-a and IL-la were not capable of 
inducing MHC class II expression (Figure 4.13 and Figures 4.16) but LCM was 
(Figure 4.15) when melanocytes were exposed to the cytokines for only 24 hours. 
However, Krasagakis et al. (1995) demonstrated increased MHC class II expression in 
response to the cytokines TNF-a, IL-la and IL-lß when melanocytes were incubated 
for 6 days with the cytokines. 
Le Poole et al. (1993b) previously reported LFA-3 expression on melanocytes but there 
was no mention of the effects of cytokines on the expression while in this present study, 
LFA-3 expression was constitutive and unaffected by cytokines (Figure 4.17). LFA-3 
expression was affected by the mitogenic content of the media (Figure 4.18). LFA-3 
expression in melanoma cells was unresponsive to cytokine modulation (Altomonte et 
al, 1993). CD40 expression in the melanocytes was negligible (Figure 4.19). The 
expression of mRNA was detected in normal melanocytes but cell surface 
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expression was not examined (Thomas et al, 1996). Melanoma cells however express 
CD40 (van den Oord et al, 1996; Thomas et at, 1996). B7-1 and B7-2 were not 
examined in this study, but previous studies have indicated that melanocytes do not 
express these cell surface molecules as determined by flow cytometry (Denfeld et al, 
1995) and reverse transcriptase-polymerised chain reaction (Thomas et al, 1996). 
In conclusion, this study showed that long term cultured melanocytes established from 
patients with vitiligo did not differ from normal melanocytes with respect to expression 
of immune-related molecules under several different media conditions. Accordingly, it 
can be suggested that there are no intrinsic defects in vitiligo melanocytes. However, 
the effect of pro-oxidants on the expression of cell surface molecules was not 
undertaken in this study, but this is a valid area for further research. With the recent 
finding that melanocytes from patients with active vitiligo have altered antioxidant 
defences (Maresca et al, 1997), exposure to pro-oxidants may reveal an intrinsic defect 
and increase the susceptibility of vitiligo melanocytes to an immune attack. 
Finally, the inability of UVB irradiation to affect constitutive ICAM-1 expression, the 
production of POMC-peptides in epidermal cells including melanocytes in response to 
UV irradiation and the immunomodulation function illustrated in this chapter indicate 
that a-MSH may exhibit a wider biological role than just pigmentation by assisting 
melanocytes to cope with UVR induced stress. If such an immunomodulatory role of a- 
MSH is also retained in situ for human melanoma cells, which are capable of local 
production of these peptides in nanomolar concentrations, then this might provide one 
mechanism by which these tumor cells could evade detection/interaction with the 
immune system. It is unclear how or whether this may play a role in vitiligo but a 
defective MC1R in vitiligo melanocytes may render them susceptible to UV-induced 
stress or other defects and lead to their destruction. As there have been no studies on the 
effects of a-MSH on pigmentation or other aspects of the biology of cultured vitiligo 
melanocytes it is difficult as yet to conclude a role for a-MSH in vitiligo. 
CHAPTER 5 
TREATMENT OF VITILIGO WITH CULTURED EPITHELIAL 
AUTOGRAFTS. 
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5.1 INTRODUCTION. 
Many patients with vitiligo suffer psychological problems because of the "cosmetic 
stigma" often associated with the disease and therefore seek treatment. As the precise 
aetiology of vitiligo is unknown, the treatment of vitiligo can be a problem for the 
dermatologist. 
Medical treatments such PUVA and steroids are often the first treatments considered (as 
discussed in Sections 1.5.1a and f respectively). However, distal extremities and 
periorificial lesions do not respond well to PUVA (Honig et al, 1994) and patients with 
segmental vitiligo also do not generally respond well to PUVA (Honig et al, 1994) or 
corticosteroid treatment (Koga, 1977). Even in patients that respond, 100% 
repigmentation is rarely achieved; for example Grimes (1997) reported that 178 patients 
had a mean repigmentation of 58% in response to topical PUVA. PUVA treatment is 
very time-consuming and maintenance therapy may be required (Kenny, 1971). Both 
topical and systemic PUVA and topical corticosteriods can have side effects (Section 
1.5.1a and f; Drake et al, 1996). Khellin and phenylalanine photochemotherapies 
(Sections 1.5.1c and d respectively) are evolving treatments with apparently fewer side 
effects, but recent reports suggest they are not as effective as conventional PUVA 
(Orrechia & Perfetti, 1992; Rosenbach et al, 1993; Procaccini et al, 1995; Alkhawajah, 
1996). 
For patients with stable vitiligo, surgery is a possibility. Surgical techniques (as 
described in Section 1.5.2) such as blister-induced epidermal grafts (Suvanprakorn et al, 
1985; Koga, 1988; Hatchome et al, 1990; Lee et al, 1991; Skouge et al, 1992; 
Matsumura et al, 1993; Mutalik, 1993; Zachariae et al, 1993; Skouge et al, 1995; Hann 
et al, 1995; Suga et al, 1996; Yang & Kye, 1998) have been used with positive results in 
patients with localised and segmental vitiligo. Patients with generalised vitiligo were 
less likely to respond and the Koebner phenomenon was a problem (Hatchome et al, 
1990). Incidences of scarring were low with this method. Mini-grafting (Section 
1.5.2c), another successful surgical technique, can be employed to determine patient 
suitability for further grafting treatment (Boersma et al, 1995; Falabella et al, 1995a) 
and for the completion of repigmentation in lesions where previous grafts did not 
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achieve 100% repigmentation (Falabella et al, 1995b). Many of these technqiues are 
combined with PUVA treatment once the recipient site has healed, to help the new 
pigmentation spread. 
Lerner et al. (1987) first described the successful treatment of piebaldism with cultured 
melanocytes and since then the use of non-cultured (Gauthier et al, 1992; Olsson & 
Juhlin, 1998) and cultured epidermal cells have been explored (Brysk et al, 1989; 
Falabella et al, 1989; Plott et al, 1989, Falabella et al, 1992; Jha et al, 1993; Olsson & 
Juhlin, 1993; Zachariae et al, 1993; Löntz et al, 1994; Olsson et al, 1994; Olsson & 
Juhlin, 1995; Kumagai & Uchikoshi, 1997; Andreassi et al, 1998; Arenberger & 
Matouskovä, 1998; Kaufmann et al, 1998). Non-cultured cell suspensions avoid the use 
of potentially harmful mitogens and serum factors and have been diluted to treat large 
areas successfully in a patient with piebaldism (Olsson & Juhlin, 1998), whereas 
cultured cells offer the possiblility of large expansion and lessen the need for several 
biopsies. Obviously the long term effects of some of the cultured cell methods have not 
been assessed. However, the use of CEA type sheets (Falabella et al, 1989; 1992; 
Kumagai & Uchikoshi, 1997 used for vitiligo treatment) have been employed for many 
years in the treatment of burns patients (e. g. 0' Connor et al, 1981; Hefton et al, 1983; 
Gallico et al, 1984; Cuono et al, 1986; Madden et al, 1986; De Luca et al, 1989; Mol et 
al, 1990), burn scar excision (e. g. Kumagai et al, 1988), leg ulcers (e. g. Faure et al, 
1987; Leigh et al, 1987; Phillips et al, 1989), junctional epidermolysis bullosa (Carter et 
al, 1987), giant congenital naevi (Gallico et al, 1989) and tattoo excision (Kumagai et 
al, 1994). 
Keratinocytes and melanocytes form a highly regulated pigmentary unit. The 
importance of keratinocytes in the control of melanocyte behaviour has been shown in 
in vitro co-culture studies (De Luca et al, 1998a & b; Valyi-Nagy et al, 1990; Haake & 
Scott, 1991; Scott & Haake, 1991; Donatien et al, 1993; Valyi-Nagy et al, 1993; 
Nakazawa et al, 1995a; Tenchini et al, 1995; Kippenberger et al, 1996; Nakazawa et al, 
1997; Kippenberger et al, 1998a; Nakazawa et al, 1998). The culture of CEA sheets is 
routine in the laboratory for the treatment of bums patients. Also, Falabella et al. (1989 
& 1992) used a similar method which was successful in many patients and recently, 4 
patients with generalised or segmental vitiligo were treated with a method almost 
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identical to ours (Kumagai & Uchikoshi, 1997). Therefore it was decided to explore the 
use of CEA sheets in the treatment of vitiligo. Three patients with symmetrical 
(generalised) vitiligo were selected for this preliminary study. 
5.2 CULTURE OF VITILIGO EPIDERMAL CELLS AS CEA SHEETS. 
The culture of CEA sheets is primarily a method for producing well integrated sheets of 
keratinocytes for subsequent grafting on to patients. In the method employed in this 
present study, CEA sheets were formed by plating epidermal cells onto i3T3 cells in 
Green's medium (as described in Section 2.2.1). As the biopsy size from the vitiligo 
patients was small (2 x 1cm elliptical) the total number of epidermal cells obtained 
ranged from 1.02 to 2.26 x 106 cells (as indicated in Table 5.1a). Therefore one T25 
flask was set up for CEA culture with the few remaining surplus cells used for culture of 
pure melanocytes or dopa staining purposes. The primary cultures were maintained for 
8 days by which time they had become confluent. The cultures were split at this point 
so that they would only be a few layers thick at most. 
VM1, VM2 and VM5 cells were frozen down at first passage until required for use. In 
the case of VM5 cells, these were very difficult to remove from the flask, even after 20 
minutes of trypsin/EDTA treatment and therefore only a few cells were retrieved. VM1 
cells were frozen for almost 6 months while VM5 cells were frozen for 10 days. VM2 
cells were eventually used for experimental purposes as the patient declined treatment. 
VM1 and VM5 secondary cells were cultured for 13 and 12 days respectively up to the 
date of grafting (indicated in Table 5.1 a). The longer culture period allowed the sheets 
to become several keratinocyte layers thick. VM4 epidermal cells were only cultured 
for 7 days as secondaries as the patient was unable to come in for the original scheduled 
grafting date. The cells were frozen for 2-3 weeks before being cultured as tertiary cells 
for the longer period of 13 days prior to grafting. 
In all cases, the keratinocytes formed colonies as expected with this methodology and 
confluent sheets were attained by 8 days. Microscopic observations indicated no 
differences in morphology between keratinocytes from normal subjects (Figure 5.1a) 
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and vitiligo patients (Figures 5.2a, 5.3a, and 5.4a for patients VM1, VM4, and VM5 
respectively). CEA sheets used for grafting were cultured for 4-5 additional days to 
allow the sheets to become several layers thick and sturdier. 
5.3 PRESENCE OR ABSENCE OF MELANOCYTES IN CEA SHEETS. 
5.3.1 Normal epidermal CEA sheets. 
Pigmentation is the desired result when grafting CEA sheets onto vitiligo lesions. It is 
necessary, therefore, to investigate the presence of melanocytes in CEA sheets. Isolated 
epidermal cells naturally contain a small population of melanocytes (1-3%) and when 
plated into a melanocyte medium, pure cultures are obtained (as indicated in Figure 3.1 
and Figure 5.1). Melanocytes reside in the basal layer of the CEA sheets (De Luca et 
al, 1988a & b; Kumagai & Uchikoshi, 1997) and melanocytes from already established 
pure cultures attached to plastic in the presence of Green's medium (Figure 3.29), 
indicating that this medium was not detrimental to these cells. The dopa staining 
methodology (as described in Section 2.8.1) was used for the detection and 
demonstration of melanocytes within the CEA sheet. 
CEA sheets of epidermal cells cultured from normal skin appeared dopa negative for 
melanocytes (Figure 5.1a) when still attached to the petri dish dishes. CEA sheets had 
several layers of keratinocytes and therefore melanocytes, if residing in the bottom layer 
of cells or within the sheet, would perhaps not be detected. Detaching a sheet with 
dispase, and treating the sheet with L-dopa prior to fixing the sheet onto a microscope 
slide also failed to reveal the presence of any melanocytes (not shown). Dopa staining 
the petri dish after the sheet was removed with dispase showed that no cells remained 
(Figure 5.1b) This suggested that if melanocytes were integrated into the sheet they 
remained there during the dispase removal of the sheet from the petri dish. 
Freshly isolated epidermal cells plated on to plastic in maintenance medium C (Figures 
5.1c) or Green's medium (Figures 5.1d) revealed a population of melanocytes within 4 
days of plating. Epidermal cells from dissociated secondary sheets plated on to 
Figure 5.1 Dopa staining of normal epidermal cells in CEA sheets and as pure 
melanocytes. Epidermal cells were isolated from normal skin and some of these cells 
were grown as CEA sheets (as described in Section 2.2.1) then treated with L-dopa (as 
described in Section 2.8.1) (a). CEA sheets were carefully removed with dispase (as 
described in Section 2.2.2) and the remaining petri dish was treated with L-dopa (b). 
Additionally, some freshly isolated cells were plated onto plastic in maintenance 
medium C (c) or Green's (d). Pure culture cells were treated with L-dopa 4 days after 
plating. Epidermal cells from dissociated secondary CEA sheets were cultured on 
plastic in maintenance medium C (e) or Green's medium (f). Cells were treated with L- 
dopa 4 days after plating. At this time melanocytes could be clearly seen in all the 
cultures. Scale bars represent 15µm (a-b) and 30µm (c-f). 
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plastic in maintenance medium C (Figures 5.1e) or Green's medium (Figures 5.10 
illustrated that melanocytes persisted in CEA sheets. 
5.3.2 Vitiligo epidermal CEA sheets (using cells from unaffected regions of skin). 
The yield of epidermal cells from the vitiligo biopsies was low and therefore, only a few 
CEA sheets could be cultured for each patient (as indicated in Table 5.2a). Staining a 
small portion of these CEA sheets was not ideal as handling such detached sheets was 
difficult; sheets contracted and tore easily. A few surplus cells were set up in 24 well 
plates under exact conditions and cultured for the same length of time. Interestingly in 
miniature CEA sheets from the first patient (VM1), melanocytes were present (as 
indicated in Figure 5.2b-e). These cells had also been frozen for 6 months before being 
cultured for transplantation and staining. 
CEA sheets from patients VM4 and VM5 were dopa negative for melanocytes (Figures 
5.3a and 5.4a respectively). Cells from these dissociated CEA sheets were further 
cultured on plastic and the presence of melanocytes was noted (Figure 5.3b-f for VM4 
and Figures 5.4b-d for VM5). This suggested that the CEA sheets did contain 
melanocytes or precursor/immature melanocytes, which could be further cultured as 
pure melanocytes. Keratinocytes were present in the VM5 culture which is not unusual 
when epidermal cells are plated on plastic in melanocyte medium. It is noted that in 25- 
50% of our normal melanocyte cultures, keratinocytes will sit down initially on plastic 
if the epidermal cell suspension is high (i. e. above 2.5 x 106 cells per T25 flask). 
Further evidence that melanocytes persist in CEA sheets is shown in Figure 3.3 for 
patient VM2, where cells were cultured as a pure culture of melanocytes from the 
dissociated primary CEA sheet. These cells had also been frozen for approximately 6 
months prior to culture. 
For both normal and vitiligo CEA cultures, the CEA sheets were generally dopa 
negative for melanocytes when stained with L-dopa. However, CEA sheets appeared to 
retain a population of dopa-positive melanocytes or immature/precursor melanocytes 
which could be cultured from the dissociated CEA sheets. 
Figure 5.2 Dopa staining of melanocytes in a CEA sheet. Epidermal cells were 
isolated from patient VM1 biopsy and cultured as primary CEA sheets (as described in 
Section 2.2.1), then frozen. Surplus cells from frozen stocks were plated into 24 well 
plates and cultured for 13 days. They were fixed and treated with PBS (a) or L-dopa 
(as described in Section 2.8.1) (b-e). Scale bars represent 15µm. 
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Figure 5.3 Dopa staining of a CEA sheet and pure culture melanocy-tes from a 
CEA sheet. Epidermal cells were isolated from patient VM4 biopsy and cultured as 
primary and secondary CEA sheets (as described in Section 2.2.1) before being frozen. 
Tertiary cells were cultured as CEA sheets in 24 well plates and treated with L-dopa (a) 
(as described in Section 2.8.1). Additional tertiary cells were cultured as pure 
melanocyte cultures on plastic in maintenance medium C (b for PBS or c-d for L-dopa 
treated cells) or Green's medium (e-f for L-dopa treated cells). Scale bars represent 
15µm (a, d, f) and 30 µm (b, c, e) 
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Figure 5.4 Dopa staining of a CEA sheet and pure culture melanocytes from a 
CEA sheet. Epidermal cells were isolated from patient VM5 biopsy and cultured as 
primary CEA sheets (as described in Section 2.2.1), then frozen. Surplus secondary 
cells were cultured in a 24 well plate and the CEA was treated with L-dopa (a) (as 
described in Section 2.8.1). Dissociated cells from these 24 well plate CEA sheets were 
cultured as pure melanocytes on plastic in maintenance medium C, then treated with L- 
dopa (b-d). Scale bars represent 15µm. 
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5.4 GRAFTING OF CEA SHEETS ONTO VITILIGO LESIONS. 
5.4.1 Case study 1- patient VM1 
The patient had symmetrical vitiligo as shown for her left and right arms just below the 
elbows (Figure 5.5a and 5.5b respectively). The patient developed vitiligo in 1995, 
with no association with other autoimmune disorders. The sister of the patient also 
suffered from vitiligo. At the time of biopsy, in June 1996 the vitiligo was stable. The 
patient had been using topical Betnovate RD ointment prior to the biopsy. The patient 
underwent surgery in December 1996. The site of the biopsy healed without 
complications or Koebnerisation. 
The lesion on the patient's left forearm (Figure 5.5c) was chosen as the grafting site. 
The patient was dermabraded (Figure 5.5d; Figure 5.6 illustrates the dermabrader) and 
the CEA sheets applied (Figures 5.5e and 5.5f; Figure 5.7 illustrates the CEA attached 
to the Tegapore backing dressing prior to grafting). The CEA applied to the lower 
region had a small hole in it. The region was dressed with yelonet, gauze and crepe. 
The backing of the CEA was removed 11 days after grafting. Initially the region was 
red and had a few crusty regions present (Figure 5.5g) but it became evident after only a 
few weeks that there was some pigmentation and within two months, the inflammation 
had settled down and pigmentation could be clearly seen (Figure 5.5h). The patient 
used moisturiser once the site had healed. A white border remained where the CEA 
sheets did not cover the dermabraded area. 
Repigmentation of the majority of the region had occurred within nine months of 
grafting and the pigmentation also appeared to have spread slightly (personal 
communication with Dr DJ Gawkrodger). The patient did not receive any additional 
PUVA treatment and sun exposure to the region was minimal during the healing and 
follow up period. 
Figure 5.5 Treatment of patient 1 (V1111) with CEA sheets. The symmetrical pattern 
of vitiligo in patient 1 is shown in the right (a) and left (b) arm prior to grafting. The 
chosen site for grafting is illustrated pre-dermabrasion (c), post dermabrasion (d) and 
during the application of CEA sheets (e-f). Healing and the start of repigmentation in 
the grafted region is illustrated for 11 days (g) and approximately 2 months (h) post 
surgery. 
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Figure 5.6 The dermabrador. 
Figure 5.7 The CEA sheet. Epidermal cells (in this case from patient VM1) were 
cultured on i3T3 cells in Green's medium (as described in Section 2.2.1) up to 
secondary culture. On the day of grafting the sheet was carefully detached from the 
petri dish with dispase and attached to a Tegapore backing dressing (as described in 
Section 2.2.2). Until grafting the sheet was immersed in Green's medium (lacking CT 
and FCS). 
Figure 5.6 
Figure 5.7 
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5.4.2 Case study 2- patient VM4 
The patient had extensive symmetrical vitiligo which began in 1982 (the symmetry of 
lesions is noted on the wrists, Figure 5.8a). At the time of biopsy, the vitiligo was 
stable and the patient had received no treatment for the condition. Although the patient 
had no association with other autoimmune diseases, an aunt had vitiligo and thyroid 
disease. The patient underwent surgery in April 1997. 
The ulnar border and palmar aspect of the right wrist (Figures 5.8b) and the right 
olecranon (elbow region) (Figure 5.8c) were selected for treatment. Once the CEA 
sheets were applied the areas were dressed as for patient 1 (Section 5.4.1) and the elbow 
and wrist immobilised for the first few weeks. The healing was slow (Figure 5.8b-c), 
and the elbow rubbed raw within the first week. The backing of the CEA sheets was 
removed a few weeks after surgery. The areas were still tender several months after 
grafting (Figures 5.8d-f). 
Mild hypertrophic scarring became obvious by September 1997. This was an 
unfortunate complication which has since largely resolved (as noted by Dr DJ 
Gawkrodger, June, 1998). At the time of scarring the patient was in the early stages of 
pregnancy although the pregnancy began post-grafting. Despite these complications, 
there has been a small amount of repigmentation (in localised areas) within the grafted 
sites, particularly at the wrist. The donor site did not scar or develop the Koebner 
phenomenon. 
5.4.3 Case study 3- Patient VM5. 
The patient had extensive symmetrical vitiligo (Figure 5.9a) which was active prior to 
the biopsy and has since continued after the biopsy. The donor site healed without 
Koebnerisation. The patient had not received any active topical treatment to the vitiligo 
lesions. The patient underwent surgery March 1997. 
Two regions on the lower back were chosen for grafting. Figure 5.9b shows the 
regions a few months after grafting and illustrates the positioning of the chosen sites. 
Figure 5.8 Treatment of patient 2 (Vl'I4) with CEA sheets. The symmetrical pattern 
of vitiligo in pateint VM4 is shown in Figure a. The ulnar and palmar regions of the 
wrist (b) and the elbow (c) were dermabraded and tertiary CEA sheets applied (areas 
shown a week after surgery). The healing of the regions is shown at approximately 3 
months post surgery (d-1). 
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Figure 5.9 Treatment of patient 3 (VM5) with CEA sheets. The extensive symmetry 
of vitiligo in patient 3 is illustrated for the back (a). The chosen sites for grafting are 
shown approximately 2-3 weeks after surgery (b), while close up photographs of the 
left (c) and right (d) side are shown prior to dermabrasion and for the right/left side post 
dermabrasion (e) and CEA application (f). The healing of the regions are shown for 1 
week (g-h), 2/3 weeks (i-j) and 2 months (k-1) post surgery. . 
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The lesion on the left was very large and the CEA sheet was grafted into the centre of 
the lesion so that it would not touch any unaffected skin (Figure 5.9c). The lesion on 
the right was a similar size to the CEA sheet and surrounded by apparently unaffected 
skin (Figure 5.9d). The application of CEA sheets is illustrated for the lesion on the 
right of the back (Figures 5.9e-f). 
At one week after grafting the areas were still very inflamed and the backing on the 
CEA sheets were firmly attached (Figures 5.9g-h). By two weeks, the sites had healed 
but were still red. At this point the backing on the CEA sheets were removed (Figures 
5.9i-j). Even after several months the two regions were very red (Figures 5.9k-1). A 
hyperpigmented ring was noted around the grafted site on the right (Figure 5.91). This 
was the site where the CEA was touching apparently unaffected skin. At the time of 
writing, 12 months post grafting, no repigmentation had occurred. 
5.5 DISCUSSION 
The treatment for vitiligo is difficult but several options are now available. These can 
be classified as non-surgical and surgical treatments (see Section 1.5 and Section 5.1). 
The use of CEA sheets to treat vitiligo patients was decided upon as the culture method 
is established in laboratory and routinuely used for the treatment of bums patients in the 
Northern General Hospital. Several groups now use the culture of autologous epidermal 
cells or pure culture melanocytes to treat vitiligo successfully (Brysk et al, 1989; 
Falabella et al, 1989; Plott et al, 1989, Falabella et al, 1992; Jha et al, 1993; Olsson & 
juhlin, 1993; Zachariae et al, 1993; Löntz et al, 1994; Olsson et al, 1994; Olsson & 
Juhlin, 1995; Kumagai & Uchikoshi, 1997; Andreassi et al, 1998; Arenberger & 
Matougkovä, 1998; Kaufmann et al, 1998) (see Table 5.2 for some of the different 
methodologies employed). 
In this preliminary study of the use of CEA sheets in the repigmentation of vitiligo, 
three female Caucasian patients, with symmetrical vitiligo were treated. The results 
were mixed with only the first patient (VM1) treated repigmenting successfully in a 
lesion on the lower arm (Figure 5.5). A good colour match was obtained within 9 
months of CEA application and no scarring seen. A border of depigmentation remained 
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around the perimeter where the grafts did not cover, although pigmentation had started 
to spread slightly into this region. Unfortunately the second patient (VM4) developed 
hypertropic scarring approximately 3-4 months after surgery. This complication has 
since subsided (noted June, 1998 over a year after grafting) but it was difficult to assess 
the presence of pigmentation (Figure 5.8). The patient became pregnant shortly after 
surgery and it is unclear whether the grafting caused the scarring or whether the 
pregnancy had contributed to the scarring during the healing period. Future patients 
will be advised against starting a pregnancy for up to 6 months post-grafting following 
the experience of patient VM4. The donor site in patient VM4 did not scar or show 
Koebnerisation. The third patient (VM5) also treated in this study demonstrated no 
repigmentation up to the time of writing (Figure 5.9). There were no complications 
with this patient and the donor site showed no Koebnerisation, although the vitiligo was 
still progressive. Interestingly, a ring of hyperpigmentation was seen around the CEA 
graft that touched unaffected skin (Figure 5.91). All of the three patients had 
generalised vitiligo. In mini-grafting tests, patients with generalised forms of the 
disease were less responsive (Boersma et al, 1995; Falabella et al, 1995a) and 
Hatchome et al. (1990) for example, has also described the failure of patients with 
generalised vitiligo to repigment to surgical methods. However, this does not rule out 
generalised patients for the treatment with surgical methods, as many patients with 
generalised vitiligo have been treated successfully. 
Kumagai & Uchikoshi (1997) treated four vitiligo patients (two with generalized and 
two with segmental vitiligo) with CEA application to dermabraded skin (see Table 5.2). 
Repigmentation with colour resembling the unaffected skin (recipient sites included the 
abdomen) was obtained usually within 6-12 months and no scarring was seen. In a 
slight variation to the method used in the thesis and Kumagai & Uchikoshi (1997), a 
Colombian group treated numerous patients with vitiligo (mainly generalized or 
segmental) with cultured epidermal autografts prepared by culturing the epidermal cells 
on plastic in an EMEM based medium (see Table 5.2 for further details) (Falabella et 
al, 1989 & 1992). The sheets were attached to petrolatum gauze following dispase 
removal from the petri dish dishes and often cut smaller before being applied to denuded 
regions (caused by liquid nitrogen induced blistering). Eleven patients showed 
repigmentation that varied from 30-100% within 6 months (Falabella et al, 1989 & 
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1992). Some patients had a variegated effect while in others the colour was uniform. 
With all patients, there was initial hyperpigmentation which receded by 6 months. 
Indirect exposure to sunlight or UVA was advised (Falabella et al, 1989; Falabella et al, 
1992; Kumagai & Uchikoshi, 1997) and patients were treated with steroid type 
ointments during the first few months (Kumagai & Uchikoshi, 1997). The patients in 
our study were advised to avoid sunlight and no PUVA/UVA or steroid treatments 
given. 
Jha et al. (1993) reported that the treatment of 3 patients with epidermal cell 
suspensions (which were cultured in the medium as described in Falabella et al. (1992)) 
injected into blisters on the lesions, induced pigmentation as early as 2 weeks. This was 
a preliminary report and only one patient had a5 months follow-up. By this stage, the 
lesion of this patient was repigmented with a good colour match. Non-cultured 
epidermal cells injected into liquid nitrogen induced blisters (Gauthier et al, 1992) or 
spread onto dermabraded regions (Olsson & Juhlin, 1998) have been employed with 
success. Gauthier et al. (1992) reported a success rate of 7 out of 11 patients with 
segmental or focal vitiligo achieving 70-100% repigmentation including lesions located 
on the wrist while Olsson & Juhlin (1998) reported that 20 out of 23 patients with either 
segmental (3 patients) or vitiligo vulgaris achieved 80-100% repigmentation. PUVA 
was used in the Gauthier study to help pigment spread. 
Keratinocyte and melanocyte co-cultures established on bovine collagen membranes 
were used to treat 3 patients successfully (Plott et al, 1989). Epidermal cell suspensions 
were seeded onto the collagen membranes in an EMEM medium containing 10% FCS 
for 24 hours and then switched to an MCDB153 medium (supplements described in 
Table 5.2) (Plott et al, 1989; Brysk et al, 1989). When the cells were 50-70% confluent 
they were transferred onto a superficially abraded region of affected skin. 
Repigmentation, although not complete, was evident after 1 month and continued for 
several months. A good colour match was obtained without scarring. In a slight 
variation on this method, Zacharaie et al. (1993) treated a facial lesion in one Asian 
patient with autologous cultured melanocytes grown in MCDB 153 medium on plastic 
(as described in Table 5.2). A good colour match was seen within 2 months after 
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grafting and the authors thought the region had a more homogenic appearance than 
other areas grafted with more conventional means. 
Olsson & Juhlin (1993) developed a unique culture method for melanocytes using a 
medium referred to as PC-1 which did not involve serum/pituitary extracts or phorbol 
esters (see Table 5.2). The melanocytes obtained were spread onto dermabraded 
regions and secured with either a gel or mesh, or cells were injected into the 
epidermal/dermal region of non-dermabraded skin. Ten patients of either Swedish or 
middle-Eastern origin were treated. Nine patients repigmented with good cosmetic 
results including one patient with active vitiligo. Another patient who had active 
vitiligo did not repigment. This PC-1 culture method was compared with a similar type 
of co-culture method used by the Brysk/Plott group (Löntz et al, 1994) but they 
preferred the PC-1 culture method. Patients with segmental (just 2 patients) and 
generalized vitiligo (both stable and moderatively active) were treated; 11 of the 27 
patients demonstrating 90-100% repigmentation (including the 2 patients with 
segmental vitiligo and 3 patients with active vitiligo) while 14 of the 27 patients had 
less than 50% repigmentation. Therefore, this study illustrated that the response of 
patients with generalised vitiligo were mixed. The trunk, face and back of the hands 
proved the most likely regions to achieve successful repigmentation, with arms and legs 
next. Elbows and fingers were the hardest. Similar results were reported by Olsson & 
Juhlin (1995). 
It is interesting to note that patient VM5 in our study, who was grafted on the back, a 
site described as relatively successful by Löntz et al. (1994) showed no repigmentation. 
Perhaps this was due to patient VM5 having a symmetrical (generalised) vitiligo or due 
to the slight progressive nature of the vitiligo. Additionally, all the patients in our study 
were treated with epidermal cells that had been in cryostorage from a few weeks to 6 
months. Patient VM1 who showed the most successful repigmentation, was grafted 
with cells that had been in storage for 6 months. Compton et al. (1998) reported 
varying melanocyte loss from CEA cultures depending on what passage the epidermal 
cells had been put in to crystorage. Patients of Scandinavian descent though were 
successfully treated with pure cultures of melanocytes that had been in cryostorage 
(Olsson et al, 1994). 
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Kaufmann et al. (1998) established pure cultures of melanocytes in a Ham's Flo 
medium (described in Table 5.2) initially used by Lerner et al. (1987) to culture 
melanocytes for the treatment of piebaldism. Melanocytes were then cultured on an 
absorbable hyaluronic acid matrix for 7 days prior to being applied to Er; YAG laser- 
ablated lesions. The grafted lesions were exposed to UVA radiation. In two patients, 
repigmentation of varying extents was seen in many of their treated lesions with good 
cosmetic results. The authors were aiming to improve the wound bed for grafting by 
using the laser treatment. In another recent study, Andreassi et al. (1998) cultured 
melanocytes in Green's medium on a biomaterial termed "Laserskin". Six out of 11 
patients with localised vitiligo showed almost complete repigmentation when these 
cultures were applied to the liquid carbon dioxide-treated lesions. Arenberger & 
Matouskovä (1998) in abstract form, have described a system in which melanocytes and 
keratinocytes were cultured on cell free pig dermis, and these composites applied to 
vitiligo lesions. Approximately 50% of the patients treated repigmented. This 
composite methodology has yet to be tried with human dermis, although patients with 
burns have been treated with human epidermal/dermal type reconstructs (Boyce et al, 
1995; Harriger et al, 1995). 
All the groups showed that repigmentation can be obtained via the use of autologous 
cultured cells. The degree of repigmentation varied and 90-100% repigmentation was 
not always achieved. Mini-grafting was suggested as a means of inducing further 
repigmentation in depigmented borders around grafts (Falabella et al, 1995b). Falabella 
and co-workers suggest that these methods only be used as a last resort and for patients 
with stable, nonprogressive vitiligo of the generalized or segmental type. Olsson and co 
workers who have also treated large groups, have shown that patients with moderately 
active vitiligo can be treated as well. Only one of the patients treated in our study 
showed good detectable repigmentation, and it is therefore vital to know if melanocytes 
are present or absent in the CEA culture method. 
Freshly isolated epidermal cells obviously contain a small proportion of melanocytes as 
pure culture of melanocytes can be achieved if cells are plated into the appropriate 
conditions (for example see Figure 3.1 and Figure 5-lb-c). It is known that 
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keratinocytes and melanocytes interact in a tightly co-ordinated unit and several studies 
have shown the importance of keratinocyte influence on melanocyte physiology in co- 
culture (De Luca et al, 1998a & b; Valyi-Nagy et al, 1990; Haake & Scott, 1991; Scott 
& Haake, 1991; Donatien et al, 1993; Valyi-Nagy et al, 1993; Nakazawa et al, 1995a; 
Tenchini et al, 1995; Kippenberger et al, 1996; Nakazawa et al, 1997; Kippenberger et 
al, 1998a; Nakazawa et al, 1998). Dopa staining of CEA sheets, attached and detached 
from the petri dishes, generally proved negative for melanocytes (shown in Figures 
5.1a, 5.3a, 5.4a), except in the case of vitiligo patient VM1 (Figure 5.2). Faure et al. 
(1987) using an argentaffin stain reported the absence of melanocytes in CEA sheets but 
in accordance with Gallico et al. (1984) saw the emergence of melanocytes in grafted 
sites. De Luca et al. (1988b) showed that CEA sheets of primary, secondary and tertiary 
level clearly contained melanocytes which was confirmed by Kumagi & Uchikoshi 
(1997) in secondary CEA sheets. In other co-culture studies, where only one layer of 
keratinocytes was present, melanocytes were easily detected by HMB-45 staining 
(Haake & Scott, 1991; Scott & Haake, 1991), or by MEL-5 staining (Valyi et al, 1990; 
Staiano-Coco et al, 1991; Valyi et al, 1993; Nakazawa et al, 1997 & 1998). 
Melanocytes were noted at early culture in the EMEM methodology (Falabella et al, 
1989; Falabella et al, 1992; Jha et al, 1993) but studies were not conducted on the sheets 
once they became fully confluent and the keratinocytes stratified (Falabella et al, 1989 
& 1992). Similarly with keratinocyte/melanocyte co-culture of Brysk et al. (1989) and 
Plott et al. (1989), melanocytes were present in subconfluent cultures as detected by the 
MEL-5 antibody. Melanocytes were detected in the grafted regions from these methods 
(Falabella et al, 1989; Brysk et al, 1989; Plott et al, 1989; Falabella et al, 1992). In the 
present study, the grafted site was not biopsied to check for the presence of 
melanocytes. 
It was difficult to assess if the CEA cultures were normal with respect to the length of 
time in culture using comparisons with other studies. Table 5.1b illustrates the length 
of time in culture for CEA sheets used on bums patients and a keloid scar patient from 
our laboratory. The primary cultures in Table 5.1b were in culture longer than the 
vitiligo CEA cultures (Table 5.1a) but in culture for a shorter period of time as 
secondaries than the vitiligo CEA cultures (Table 5.1a). The vitiligo keratinocytes 
formed colonies as expected by this method, and were confluent within 8 days. Gallico 
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et al. (1984), for example, noted that it took 10 days to obtain a confluent sheet of cells 
from burns patients. Falabella et al. (1989 & 1992) used CEA sheets as primaries and 
cultured the cells for 21 days. However, during this period, the calcium level was raised 
to obtain stratified layers of keratinocytes. Kumagai & Uchikoshi (1997) generally 
passaged the cells twice within a3 week period. On light microscopy the keratinocytes 
from the vitiligo patients looked identical to keratinocytes from normal subjects (see 
Figure 5.1a for normal keratinocytes and Figures 5.2a, 5.3a and 5.4a for vitiligo 
keratinocytes). 
From this study it has become apparent that the presence of melanocytes in CEA sheets 
is difficult to detect. This could be due to skin type and the genetic predisposition for 
low pigmentation activity in skin types I and II. Bessou et al. 1996 found that 
melanocytes from skin type I in epidermal/dermal reconstructs were weakly dopa 
stained when the epidermis was salt split from the dermis. It is also a possibility that 
keratinocytes may downregulate melanocyte dopa oxidase activity in this culture system 
and this requires further investigation. Kippenberger et al. (1996) however, have 
demonstrated that melanocytes cultured in the presence of keratinocytes or phorbol 
esters had enhanced transcription of melanogenic enzymes tyrosinase, TRP-1 and TRP- 
2. The vitiligo keratinocytes in this present study did not appear to be abnormal from 
visual observation and behaved similarly with respect to proliferation. The CEA 
technique merits further investigation for repigmentation of vitiligo as the first patient 
treated was clearly successful. In future, selection of patients will be more thorough. It 
is perhaps of interest to include patients with focal or segmental forms of the disease in 
the study. In an attempt to learn if patients are suitable for grafting, patients will 
initially be treated in a small area as a test site to determine repigmentation and scarring. 
This follows along the lines of using a few minigrafts as advocated by Boersma et al. 
(1995) and Falabella et al. (1995a), but our patients will receive small CEA sheets. 
Only then will patients be offered treatment of larger areas. 
CHAPTER 6 
FINAL DISCUSSION. 
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6.1 FINAL DISCUSSION. 
Vitiligo is an acquired idiopathic hypomelanotic disease. While not life threatening, it can 
psychologically affect many patients, in particular those with darker skin, where the 
contrast between the normal skin colour and depigmented milky white patches is more 
evident. The aetiology remains unclear although several hypotheses exist including 
immune, neuronal and self-destructive (as discussed in Section 1.4). Le Poole et al. 
(1993a) and Hautmann & Panconesi (1997) have described separate convergence theories 
in which interaction between many of the individual theories were proposed. Various 
distributional patterns exist such as segmental and acrofacial and it was proposed that 
segmental vitiligo was a separate form of the disease to non-segmental (Koga, 1977). This, 
together with the various overlapping hypotheses suggest that vitiligo is a syndrome of 
diseases that results in the same endpoint. A range of medical and surgical techniques 
(Sections 1.5,5.1 and 5.5) can improve the appearance of the lesions, by causing 
repigmentation. However, many patients do not respond to any treatments. PUVA, one of 
the main medical therapies, requires several sessions before a response is necessarily seen 
and up to 100 treatments or more are often needed (summarised in Grimes, 1993; Drake et 
al, 1996; Grimes, 1997). Mini-grafting is a useful technique for determining the suitability 
of patients for surgical methods (Boersma et al, 1995; Falabella et al, 1995a). 
The study of vitiligo is important. The determination of the aetiology will not only benefit 
vitiligo patients in terms of their treatment and cessation of the progression of the disease, 
but may be of some importance in the treatment of melanoma. At opposite ends of the 
spectrum, vitiligo results in the destruction of melanocytes, and melanoma cells are 
uncontrollable proliferating cells. Also patients with melanoma who develop 
hypomelanotic rings which are vitiligo-like often have a better survival prognosis (Barnes 
& Nordlund, 1989). However, before an understanding of vitiligo melanocytes can be 
achieved, further characterisation of normal melanocytes is required. The main function of 
melanocytes is to produce melanins which once transferred to keratinocytes, in theory 
protect the skin against harmful ultraviolet irradiation. 
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The number and type of in vitro studies performed on normal melanocytes have increased 
over the past decade. However, media conditions vary between the different investigators 
and neonatal foreskin melanocytes are preferentially used as these are easier to culture 
(discussed in Section 3.1.1). In vitiligo, cutaneous melanocytes throughout the body are 
destroyed, and persons of any age can become affected by the disease. Therefore, the work 
in this thesis was carried out using adult cutaneous melanocytes. Morphology, proliferation 
and pigmentation of normal adult melanocytes was assessed in response to ECM proteins, 
UVB irradiation and a-MSH under various media conditions. 
A range of ECM proteins have been shown previously to influence morphology (Gilchrest 
et al, 1985; Ranson et al, 1988a; McClenic et al, 1989; Hara et al, 1994; Nakazawa et al, 
1995b), proliferation (Ranson et al, 1988a; Mortarini et al, 1995) and pigmentation (Ranson 
et al, 1988a; Buffey et al, 1994; Nakazawa et al, 1995b) in normal melanocytes. In this 
study (discussed fully in Chapter 3), a variety of individual and cell-derived ECM proteins 
were compared and were found to be unable to stimulate melanocyte dendricity or have a 
significant effect on the morphology of melanocytes (Section 3.2.4). The greatest and most 
consistent effects of ECM proteins on proliferation and pigmentation were seen when 
melanocytes were cultured in a mitogen reduced medium (Sections 3.3.4-3.3.5,3.4.4- 
3.4.9). In contrast to ECM proteins, UVB stimulation of melanocytes was greatest when 
the cells were cultured in a mitogen rich medium such as medium 1. Dendricity and cell 
body size were increased and pigmentation was significantly increased in response to UVB 
irradiation (Sections 3.2.5 and 3.4.8) as previously reported by several authors (Friedmann 
& Gilchrest, 1987; Libow et al, 1988; Tomita et al, 1988; Friedmann et al, 1990a&b; 
Ramirez-Bosca et al, 1992; Aberdam et al, 1993; Abdel-Malek et al, 1994; Im et al, 1994; 
Romero et al, 1994; Duval & Schmidt, 1997). UVB irradiation halted cell proliferation and 
reduced cell viability (Section 3.3.4) in agreement with several other studies (Friedmann & 
Gilchrest, 1987; Ramirez-Bosca et al, 1992; Abdel-Malek et al, 1994b; Barker et al, 1995). 
In media where CT had been removed (media 10 and 24), the pigmentary response was 
much reduced and this was in agreement with Im et al. (1998) who also reported that 
melanocytes cultured in the absence of cAMP agents while undergoing UVB irradiation, 
failed to pigment. 
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The role of a-MSH as a pigmentary hormone in man is controversial. While in vivo studies 
have shown clear pigmentary responses (Lerner & McGuire, 1961 & 1964; Levine et al, 
1991), only over the past 4 years have in vitro studies indicated a role for a-MSH in human 
pigmentation (Hunt et al, 1994a, b&c; Abdel-Malek et al, 1995; McLeod et al, 1995; 
Maeda et al, 1996; Suzuki et al, 1996). Recently, Im et al. (1998) reported that a-MSH 
may play a part in modulating the melanocyte response to UVB irradiation. Additionally, 
UVB increased the expression of MC1R (Funasaka & Ichihashi, 1997; Funasaka et al, 
1998), as did UV-induced keratinocyte-derived factors ADF (Funasaka & Ichihashi, 1997) 
and endothelin-1 (Funasaka et al, 1998; Tada et al, 1998). In this present study 
reproducible melanogenic effects of a-MSH were only seen under a small number of media 
conditions. Increased proliferative and melanogenic effects were much more evident in 
media containing bFGF, (Sections 3.3.2 and 3.4.2); melanocytes cultured in medium 23, 
which contains only bFGF, showing significant increases in proliferation, dopa oxidase 
activity and melanin content. However, the evolving literature showing that POMC 
peptides are now produced in the skin (Thody et al, 1983; Farooqui et al, 1993; Schauer et 
al, 1994; Iyengar, 1995; Kippenberger et al, 1995; Slominski et al, 1995; Chakraborty et al, 
1996; Wintzen et al, 1996; Teofoli et al, 1997; Wakamatsu et al, 1997; Can et al, 1998) 
indicated a much wider role for a-MSH and other POMC peptides. a-MSH has been 
shown to influence melanocyte attachment to ECM proteins (Hunt et al, 1993; Scott et al, 
1997) and alter the melanocyte cytoskeletal protein structures (Scott et al, 1997). It is 
proposed that a-MSH has a role in modulating oxidative stress through increasing 
tyrosinase activity, which traps free radical species (Valverde et al, 1996b) and this was 
recently linked to the pathogenesis of vitiligo as vitiligo melanocytes of the unaffected and 
perilesional skin were shown to have lower amounts of IR a-MSH than control skin, 
reported in brief (Graham et al, 1998). This theory, along with the one proposed by Liu et 
al. (1995) (discussed in Chapter 4), remain speculative at the moment. A further putative 
role for a-MSH as an immunomodulatory peptide is mentioned below. 
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An epidermal/dermal reconstruct model has been developed in Dr S Mac Neil's laboratory 
over the past 6 years. In preliminary studies normal melanocytes were added to these 
composites to examine the usefulness of this model for investigating pigmentation and for 
the study of vitiligo (Section 3.4.10). Bessou et al. (1997a) proposed the use of an 
epidermal/dermal reconstruct as a means of investigating vitiligo. Their model is well 
established for the study of the effects of UVB irradiation (Bessou et al, 1995 & 1996) and 
has been used to examine the effects of known pigmentary and depigmentary agents 
(Bessou et al, 1997c). However, their model does not include the live fibroblasts being 
added to the dermis. The work in this thesis shows that the presence of fibroblasts plays an 
important role in preventing pigmentation as was noted in composites with (Figures 3.30 
and 3.34) and without added melanocytes (Figure 3.33). This is intriguing since Bessou et 
al. (1995 & 1996) reported ex vivo construction of skin types I-VI phototypes with and 
without UVB stimulation in composite models without added fibroblasts. Hence it is 
possible that soluble fibroblast-derived factors may remain in the dermis employed in the 
experiments described by Bessou and coworkers. 
The presence of fibroblasts and keratinocytes induced higher levels of pigmentation in 
melanocytes cultured on a dermal substitute than melanocytes alone on a monolayer 
(Archambault et al, 1995). Moreover, the effect of fibroblasts alone on pigmentation was 
not examined although fibroblasts were found to significantly enhance melanocyte survival 
in response to UVB irradiation (Archambault et al, 1995). A second finding of the current 
work demonstrated the importance of the basement membrane proteins. When the dermis 
was stripped of these, melanocytes migrated out of the basal layer of the reconstructed 
epidermis and a significant amount of pigmentation was seen. Overall, there appeared to be 
a loss of melanocytes from the composites. Melanocytes bind to ECM proteins through 
integrins (Scott et al, 1992; Danen et al, 1993; Morelli et al, 1993; Zambruno et al, 1993) 
but they also interact with keratinocytes through E-cadherins (Tang et al, 1994; Nakazawa 
et al, 1995a). De Luca et al. (1988a) illustrated the importance of keratinocytes fixing the 
position of melanocytes within the basal layer of CEA sheets. Against this the results seen 
in the composite model in the present study seem unusual. In the CEA sheet, a feeder layer 
is present and might provide the additional signals or ECM proteins seen in composites 
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where the basement layer was already present. The high level of pigmentation seen may 
relate to the melanocytes being stressed because they are not located at the correct level of 
the composite. a-MSH had no effect on pigmentation in the composites. On the other 
hand, CT was initially present in the Green's medium, and could have had long term 
masking effects. It was also noted, in monolayer cultures of melanocytes, that reproducible 
results were only seen with a-MSH when cells had been cultured for long periods in a 
maintenance medium devoid of CT (Section 3.4.2). Further work is needed to fully assess 
the effects of fibroblasts and keratinocytes, and the contribution of the basement membrane 
to the structure and pigmentation in these composites. 
Over the past decade, several authors have examined different functional aspects of cultured 
melanocytes from unaffected/perilesional regions of vitiligo skin. Naturally, the growth of 
vitiligo melanocytes has been studied and compared to that of normal melanocytes. While 
Puri et al. (1987) noted that these melanocytes had defective growth which could be 
improved by fibroblast-derived growth factors (Majumdar et al, 1987; Puri et al, 1989), 
other groups have achieved successful culture of vitiligo melanocytes, and found that such 
cells show no apparent deficiencies when compared to normal melanocytes (Medrano & 
Nordlund, 1990; Im et al, 1992; Jee et al, 1993; Im et al, 1994; Bessou et al, 1997b). In 
this thesis, the proliferation of melanocytes from vitiligo patients was not clearly different 
to that of normal melanocytes. While the results (Figure 3.20) showed no significant 
differences, melanocytes from three patients who were in their seventh and eigth decade at 
the time of donation had lower proliferation rates than their paired normal melanocytes who 
were from donors that were significantly younger. The significantly longer time taken to 
obtain sufficient numbers of vitiligo melanocytes for experimentation was probably due to: 
(a) the initial small biopsy size from vitiligo patients; (b) the initial culture of vitiligo 
epidermal cells in Green's medium, which although is not detrimental to melanocytes, is 
not ideal for proliferation; and (c) the possible effect of the donors' age. Melanocytes from 
patient VM4 had a similar proliferative rate to normal melanocytes. The age of this patient 
was similar to the median age of the normal subjects (as discussed in Section 3.5.1). Age 
of the donor has been reported to be an important factor in the proliferation of melanocytes 
(Abdel-Malek et al, 1994a). Morphologically, vitiligo melanocytes were very similar to 
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normal melanocytes (Section 3.2.1) (Medrano & Nordlund, 1990; Im et al, 1992; Jee et al, 
1993; Im et al, 1994; Bessou et al, 1997a) and responded in the same way to certain stimuli 
as did the normal melanocytes (Sections 3.2.5-3.2.6). 
Experiments to investigate the pigmentary responses to UVB were completed in two 
cultures of vitiligo melanocytes. VM1 melanocytes responded with increased melanin 
production to 7 doses of UVB, when cultured in all three media, but VM3 melanocytes 
were much less responsive (Section 3.4.9). Notwithstanding this observation, no firm 
conclusions can be drawn from these preliminary data. Interestingly, patient VM1 
responded positively to treatment with CEA sheets (discussed later in this section) whereas 
patient VM5, from whom VM3 melanocytes were derived, did not. Im et al. (1994) 
reported that melanocytes from Korean vitiligo patients and from controls responded in a 
similar manner to UVB irradiation. This appears to be the only study in which monolayer 
cultures of vitiligo melanocytes were used to examine pigmentary reponses. An 
epidermal/dermal reconstruct model has been employed to examine combinations of normal 
and vitiligo melanocytes and keratinocytes (Bessou et al, 1997a). These authors reported 
that there were no apparent abnomalities in any of the composites containing vitiligo cells 
and suggested that an extrinsic factor was the likely cause of vitiligo. 
There is much evidence to suggest an immune aetiology for vitiligo (Section 1.4.3) but it 
remains unclear whether the reported immune irregularities occur as a result of primary 
immune dysregulation or as a secondary response to some other undefined precipitating 
factor. In only one study was there an indication that immune dysregulation could be the 
primary cause. D'Amelio et al. (1991) described two first-degree relatives of patients with 
vitiligo who had abnormalities in their peripheral T cells, and who later developed vitiligo. 
MHC class II and ICAM-1 have been shown to be abnormally upregulated in perilesional 
vitiligo melanocytes (Al Badri et al, 1993). Le Poole et al. (1993a) hypothesised an 
infectious agent as a possible cause and, more recently, CMV has been suggested as a 
precipitating factor (Grimes et al, 1996). Both Boissy et al. (1991) and Im et al. (1994) 
reported that the majority of cultured vitiligo melanocytes had irregular RER, yet no other 
abnormalities, such as differences in proliferation or pigmentation, were 
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noted. Such a defect might however, result in abnormal expression of immune-related cell 
surface molecules. 
In this study, the basal and cytokine-stimulated expression of ICAM-1, MHC class I and 
class II molecules were examined. Under all the conditions used, normal and vitiligo 
melanocytes had similar constitutive and cytokine (IFN-y and TNF-a) stimulated levels of 
these cell-surface molecules (Chapter 4) indicating that no intrinsic defect could be 
demonstrated in these vitiligo melanocytes. Factors which increase oxidative stress such as 
hydrogen peroxide can enhance the expression of cell surface molecules (e. g. Ikeda et al, 
1994a; Little et al, 1998). Maresca et al. (1997) reported that vitiligo melanocytes had 
altered levels of antioxidants and this was also seen in the epidermis of vitiligo lesions 
(Passi et al, 1998). Schallreuter and co-workers have reported many defects in vitiligo 
epidermis (e. g. Schallreuter et al, 1991,1994a, c, d, & 1996b; as discussed in Section 
1.4.4a) and proposed that these function to increase hydrogen peroxide generation. 
Therefore, a study to examine the expression of immune-related cell-surface molecules in 
vitiligo melanocytes stimulated with free radical forming agents would be an obvious step, 
using melanocytes from patients with both active and stable disease. This study used 
patients with generalised (symmetrical) vitiligo, with the majority of patients being in the 
stable phase. In the few studies on vitiligo melanocytes which are reported, integrin 
expression in vitiligo melanocytes was normal (Le Poole et al, 1997) whereas calcium 
uptake was defective (Schallreuter-Wood et al, 1996). An organotypic study has shown 
that vitiligo and normal melanocytes migrated in a similar fashion (Le Poole et al, 1994b). 
Therefore vitiligo melanocytes may be defective in some respects but not in others. 
One of the main findings from this thesis was the ability of a-MSH to oppose the actions of 
TNF-a in modulating ICAM-1 expression in normal melanocytes (Sections 4.3.1-4.3.5). 
This was reported in abstract form by Hewitt et al. (1993), and this phenomenon was also 
seen in melanoma cells (Morandini et al, 1998). Other studies using non-melanocytic cells 
have shown that a-MSH can reduce the expression of immune-related cell surface 
molecules as well (Köck et al, 1991; Luger et al, 1993). a-MSH however was not effective 
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against IFN-y-stimulated ICAM-1 expression (Section 4.3.6) and therefore this does raise 
the question of the importance of the findings and whether, in vivo, where melanocytes 
would see a greater range of cytokines, an immunomodulatory effect would be apparent. 
cAMP elevating agents however were able to oppose the actions of IFN-y in melanoma 
cells (Morandini et al, 1997), so this effect may have more importance in the clinical 
context of malignant melanoma. To examine the importance of these findings, the use of 
LCM containing many different cytokines would be useful. Morandini et al. (1998) have 
shown that the effect is linked to a reduction in the expression of ICAM-1 at the mRNA 
level, and further studies in our laboratory using melanoma cells indicate that the 
transcription factor NFi B is a key control point (Haycock et al, 1998a & b). Other studies 
have indicated the role of NFiB in modulating the response to a-MSH in other cells 
(Brzoska et al, 1998; Kalden et al, 1998). 
This finding of a-MSH opposing cytokine-stimulated ICAM-1 expression has many 
implications. One is that, in normal melanocytes, a-MSH may play a role in protecting the 
melanocyte from unwanted immune attack during UV-induced or chemically-induced 
stress, where cytokines would be produced. In accordance with this, UVR did not enhance 
constitutive ICAM-1 expression (Section 4.2.4). Kinnbauer et al. (1991) found that UVR 
reduced the level of cytokine-enhanced ICAM-1 expression. Additionally, if this feature is 
maintained in malignant melanoma, it could be a way of providing escape from immune 
surveillance. There could be some relevance to vitiligo but it is a difficult question to 
answer, and was outside the scope of this thesis not least because of time constraints. 
Interestingly, the presence of a-MSH receptors has not been examined on in vitro cultured 
vitiligo melanocytes, and the effect of a-MSH on pigmentation in these melanocytes has 
not been reported. Liu et al. (1995) proposed that a-, ß- and y-MSH peptides may play a 
role in the pathogenesis of vitiligo vulgaris. One possibilty is that vitiligo melanocytes may 
have a defective MC1R. This is plausible following the discovery of a nonfunctional 
MC1R variant (Frändberg et al, 1998) or they may develop an altered sensitivity to MSH 
peptides in response to MSH overproduction in the skin, as proposed by Liu et al. (1995). 
Obviously any alterations in the MC1R which prohibit the activation of the PKA pathway 
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would suggest a loss of protective measures against the immune system. However, this 
remains speculation at the time of writing. 
While an immunomodulatory role of a-MSH can be demonstrated in vitro, it is necessary 
to know if this reduction in ICAM-1 expression can translate into a reduction of T cell 
binding and activation. Melanocytes have been shown to bind T cells (Nickoloff et al, 
1991; Le Poole et al, 1993b) and are capable of presenting antigen and activating T cells 
(Le Poole et al, 1993b). Preliminary studies of T cell binding to normal melanocytes were 
unsuccessful (as discussed in Section 4.6) and other methods using flow cytometry may be 
required to make progress in such sudies. Methods are currently being investigated to find 
the best way to study T cell binding and activation in both normal and malignant 
melanocytes. 
The CEA approach was used to treat three patients with vitiligo. This culture, while 
primarily a keratinocyte culture, has been reported to retain the stable keratinocyte to 
melanocyte ratio (De Luca et al, 1988a & b). While other groups clearly demonstrated the 
presence of melanocytes in CEA sheets (De Luca et al, 1988b; Kumagai & Uchiskoshi, 
1997), in the majority of cultures set up in this laboratory melanocytes, were not detected 
using L-dopa staining. Ongoing studies in the laboratory have recently identified the 
presence of melanocytes in CEA sheets by staining melanocytes for TRP-1 (personal 
communication J Phillips and S Mac Neil, 1998). Dissociated sheets of varying passage 
number always yielded melanocytes (Figures 3.3,5.1,5.3-5.4, Section 5.3). Further 
investigation is required to explore why the detection of melanocytes using L-dopa staining 
was not possible in CEA sheets. One hypothesis is that the keratinocytes are actually 
downregulating the melanogenic capacity of the melanocyte, but a study by Kippenberger 
et al. (1996) has shown that under co-culture conditions, melanocytes actually had 
increased levels of the melanogenic enzymes. Bessou et al. (1996) noted that in epidermal 
salt splits from epidermal/dermal reconstructs, melanocytes of skin type I donors were very 
weakly stained with L-dopa and it was difficult often to identify melanocytes. Therefore it 
seems likely the inherent genetics may make the melanocytes in the current study difficult 
to detect as they were predominantly from skin types I and II. Orlow et al. (1993) reported 
184 
that tyrosinase was associated with stage III and stage IV melanosomes, of which few are 
found in persons with skin types I and II whereas TRP-1 is associated with stage I and II 
melanosmoes. This might indicate why melanocytes could be detected by TRP-1 staining 
and not by L-dopa staining when in contact with their skin counterparts, the keratinocytes. 
It was difficult to assess if the vitiligo keratinocytes proliferated at a similar rate to normal 
keratinocytes in CEA sheets. However, light microscopy examination showed that normal 
and vitiligo keratinocytes were morphologically identical. Vitiligo keratinocytes formed 
colonies, and a confluent sheet was produced within 8 days -a time similar to that reported 
by Gallico et al. (1984) for cells cultured from burns patients. Keratinocytes from vitiligo 
patients have been implicated in the cause of the disease because of damage observed in the 
lesional areas (Breathnach et al, 1966; Ishii & Hamada, 1981; Moellmann et al, 1982; 
Bhawan & Bhutani, 1983; Kao & Yu, 1990; Hann et al, 1992; Ahn et al, 1994; Yagi et al, 
1997). Results from a preliminary co-culture study implied that vitiligo keratinocytes may 
be defective (Le Poole et al, 1991) while increased levels of tenascin seen in vitiligo lesions 
might be explained by its overproduction by vitiligo keratinocytes (Le Poole et al, 1997). 
Defects in the epidermis, as previously mentioned in this section, could also result from 
defects in the keratinocytes. Bessou et al. (1997a) though, found no abnormalilties when 
vitiligo keratinocytes were cultured in an epidermal/dermal model. 
The treatment of the patients raised several questions. One patient (VM1) showed 
successful repigmentation, although a perimeter of vitiligo remained around the edge, 
where the CEA sheets did extend to the margins of dermabrasion (Figure 5.5). The 
melanocytes from this patient were also highly responsive to UVB stimulation (Section 
3.4.9). One patient (VM5) did not repigment, but this patient had active vitiligo. 
Additionally, the cells from this patient were not responsive to UVB stimulation (Section 
3.4.9). The third patient (VM4) developed transient hypertrophic scarring which was a 
problem not anticipated. For this patient there has been slight pigmentation in small 
regions and the scarring complications are still resolving so it is unclear what the final 
outcome will be. Due to the success of the first patient and other successful reports using 
similar methods in vitiligo patients (Falabella et al, 1989 & 1992; Kumagai & Uchishoki, 
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1997), further work is underway to explore this approach as a treatment for vitiligo patients. 
Following the preliminary study the protocol is now to treat a small test area, to see if the 
patient will respond positively to grafting and not develop scarring. The patients treated in 
this study had symmetrical generalised vitiligo. While patients with generalised vitiligo 
can respond to surgical methods with cultured cells, the success rate is approximately 50% 
as illustrated by Löntz et al. (1994), who used cultured melanocytes, and Boersma et al. 
(1995) and Falabella et al. (1995a) who used the mini-grafting technique. It would 
therefore be of interest to include patients with segmental or focal forms of the disease in 
the study. 
In conclusion, vitiligo melanocytes that were in culture long term did not differ appreciably 
from normal melanocytes in proliferation, morphology or in basal and cytokine stimulated 
levels of ICAM-1, MHC class I and class II expression. This is in agreement with several 
other studies in which no abnormalities in melanocyte parameters were noted (Im et al. 
1994; Le Poole et al. 1994b; Bessou et al. 1997a; Le Poole et al. 1997) and would suggest 
that an extrinsic factor is responsible. However, other studies, for example those by 
Schallreuter-Wood et al. (1996) and Maresca et al. (1997), have indicated abnormalities in 
cultured vitiligo melanocytes. Thus, in vitro studies so far provide conflicting data and the 
aetiology of vitiligo remains elusive. As yet, there is little evidence to support an intrinsic 
defect in the melanocyte; theories of autoimmunity, intrinsic keratinocyte defects or some 
precipitating extrinsic factor are all under investigation. 
APPENDICES. 
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MATERIALS. 
Bovine pituitary extract was obtained from Advanced Protein Products, Brierly Hill, 
West Midlands, UK. 
Acetic acid, buffered formalin, cuvettes UV range (disposable), eosin yellowish, ethanol 
(99.7-100%v/v), glutaraldehyde, hydrochloric acid, paraformaldehyde, poly-l-lysine 
coated slides, silver nitrate, sodium bicarbonate, sodium citrate, sodium 
dodecylsulphate, sodium hydroxide, sodium thiosulphate anhydrous and 
Tris(hydroxymethyl)methylamine-buffered saline (TBS) were obtained from BDH 
Merck Ltd, Magna Park, Lutterworth, Leicestershire, UK 
HLA-DR, DQ, DP PE-conjugated antibody, mouse IgGI FITC-conjugated antibody 
control, mouse IgGI PE-conjugated antibody control, mouse IgG2a FITC-conjugated 
antibody control and mouse IgG2a PE-conjugated antibody control were obtained from 
Becton Dickinson, Cowley, Oxford, UK. 
Dispase, y-interferon tumour (IFN-y) and necrosis factor-a (TNF-a) were obtained from 
Boehringer Mannheim UK, (Diagnostics and Biochemicals) Ltd, Bell Lane, Lewes, East 
Sussex, UK 
OCT mounting medium was obtained from Brights' Instrument Company Ltd, 
Huntingdon, Cambridgeshire, UK. 
Tissue culture plastics were obtained from Coming Costar Corporation, Cambridge, 
MA, USA. 
Anti-CD45 (leukcyte common antige) polyclonal horseradish peroxidase HRP- 
conjugated antibody, immunoglobulin HRP negative control, rabbit anti-human S100 
polyclonal antibody and mouse anti-human collagen IV antibody were obtained from 
Dako Ltd, High Wycombe, Bucks, UK. 
Trypsin was obtained from Difco Laboratories, Detroit, Michigan, USA. 
Ligaclips were obtained from Ethicon Inc, Somerville, New Jersey, USA. 
Xylene was obtained from Genta Medical, York, UK 
Bovine pituitary extract (BPE), Dulbecco's Modified Eagle's medium (DMEM), 
Fungizone, normal goat serum, newborn calf serum (NCS) and RPMI medium were 
obtained from Gibco BRL, Life Technologies, Paisley, UK. 
Foetal calf serum (FCS) was obtained from GlobePharm Limited, Esher, Surrey, UK. 
Horse and swine serum were obtained from Harlan Sera-lab Ltd, Crawley-Down, UK. 
Acetone was obtained from Hillcoss Pharmoceuticals, Burnley, UK. 
Gold chloride was obtained from Johnson Matthey Chemicals, Royston, Herts, UK 
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Tegapore backing dressings were obtained from 3M Medical-Surgical Division, St. 
Paul, MN USA. 
LymphoprepT"i and Uni-Sorb T+B nylon wool columns were obtained from Nycomed 
Pharma AS, Oslo, Norway. 
Mouse anti-human ICAM-1 monoclonal antibody was obtained from R and D Systems 
Europe, Barton Lane, Abingdon, Oxon, UK 
CD40 FITC-conjugated antibody, HLA-ABC FITC-conjugated antibody, ICAM-1 
(CD54) PE-conjugated antibody and LFA-3 (CD58) FITC conjugated antibody were 
obtained from Serotec Ltd, Kidlington, Oxford, UK. 
Paraplast was obtained from Sherwood Medical, St. Louis, MO. USA. 
Adenine, adrenocorticotropic hormone (ACTH), 3-amino-9-ethyl carbozole, 
bisbenzimide (Hoechst 33258), bovine serum albumin, calcium chloride, Chelex 100, 
collagen IV, collagenase A, cytochalasin D, deoxyribonucleic acid (bovine DNA), N, N- 
dimethyl formamide, basic fibroblast growth factor (bFGF), L-3,4- 
dihyroxyphenylalanine (L-dopa), dimethylsulphoxide (DMSO), epidermal growth factor 
(EGF), ethylenediaminetetracetic acid (EDTA), fibronectin, Giemsa solution, L- 
glutamine, glycerol, heparin, HEPES, HRP-conjugated f(ab') anti-mouse Ig, human 
serum albumin, hydrocortisone, hydrogen peroxide, IgGI isotype control monoclonal 
antibody, insulin, 3-isobutyl-l-methylxanthine (IBMX), laminin, magnesium chloride, 
MCDB151, MCDB153, a-melanocyte-stimulating hormone, melanocyte growth 
medium kit, multiwell plates coated with bovine subendothelial matrix, nystatin, 
penicillin/streptomycin, o-phenylenediamine, phorbol 12-myristate 13 acetate (PMA), 
polyoxyethylenesorbitan monolaurate (Tween/Tween-20), sodium acetate, sodium 
azide, sodium chloride, sodium deoxycholate, synthetic melanin, apo-transferrin 
(human), triiodo-L-thyronine, Triton 100X, trypsin/EDTA and urea were obtained from 
Sigma Chemicals Ltd, Poole, Dorset, UK 
Haematoxylin was obtained from Surgipath Medical Industries, Canada. 
UV-B Helarium 40W lamps (Arimed B) were obtained from Sun Health Services Ltd, 
Jarvvis Brook, Crowborough, East Sussex, UK 
Phosphate buffer saline tablets were obtained from Unipath Ltd, Basingstoke, 
Hampshire, UK 
Biotinylated anti-rabbit IgG antibody, biotinylated anti-mouse IgG antibody, Vectastain 
ABC (Avidin/Biotin Complex) kit and Vector alkaline phosphatase substrate kit were 
obtained from Vector Laboratories, Peterborough, UK. 
Safranin was obtained from Vickers Labs, Burley in Wharfedale, West Yorks, UK. 
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